National Comprehensive Cancer Network®

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Antiemesis

Version 2.2020 — April 23, 2020

NCCN.org

NCCN Guidelines for Patients®

Continue

National Comprehensive Cancer Network®

NCCN Guidelines Version 2.2020
Antiemesis

NCCN Guidelines Index
Table of Contents
Discussion

David S. Ettinger, MD/Chair †
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

***Michael J. Berger, PharmD/BCOP, Vice Chair Σ**
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Sally Barbour, PharmD, BCOP, CPP Σ ‡ †
Duke Cancer Institute

Jason Bergsbaken, PharmD, BCOP Σ
University of Wisconsin Carbone Cancer Center

Debra Brandt, DO †
Yale Cancer Center/Smilow Cancer Hospital

George E. Brown, RPh, MS, BCOP Σ
Case Comprehensive Cancer Center/ University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute

Jennie R. Crews, MD †
Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance

Eun Jeong Kim, PharmD, MS Σ
Stanford Cancer Institute

Steve Kirkegaard, PharmD Σ †
Huntsman Cancer Institute at the University of Utah

Dwight D. Kloth, PharmD, BCOP Σ
Fox Chase Cancer Center

Kelsey Klute, MD †
Fred & Pamela Buffett Cancer Center

Mark Kris, MD Þ †
Memorial Sloan Kettering Cancer Center

Dean Lim, MD †
City of Hope National Medical Center

Charles Loprinzi, MD †
Mayo Clinic Cancer Center

Cynthia X. Ma, MD, PhD † Þ
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Victoria Maurer, MSN, OCN, RN †
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Renee K. McAlister, PharmD, BCOP Σ
Vanderbilt-Ingram Cancer Center

Rutika Mehta, MD †
Moffitt Cancer Center

Laura Boehnke Michaud, PharmD, BCOP † Σ
The University of Texas MD Anderson Cancer Center

Rudolph M. Navari, MD, PhD, FACP †
O'Neal Comprehensive Cancer Center at UAB

Kim Noonan, MS, ANP, AOCN, RN # ‡
Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center

Grazyna Riebandt, PharmD, BCOP £ ‡
Roswell Park Cancer Institute

Eric Roeland, MD † £
Massachusetts General Hospital Cancer Center

Hope S. Rugo, MD † ‡
UCSF Helen Diller Family Comprehensive Cancer Center

Ila Saunders, PharmD Σ ‡
UC San Diego Moores Cancer Center

Bridget Scullion, PharmD, BCOP £
Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center

Maria Silveira, MD £
University of Michigan Rogel Cancer Center

Alyssa Wolf, MSN, BS
Abramson Cancer Center at the University of Pennsylvania

[NCCN Guidelines Panel Disclosures]

NCCN
Miranda Hughes, PhD
Dorothy A. Shead, MS

Continue

‡ Hematology/ Hematology oncology
Þ Internal medicine
† Medical oncology
# Nursing
Σ Pharmacology
£ Supportive care including palliative, pain management, pastoral care, and oncology social work
* Discussion section committee member

National Comprehensive Cancer Network®

NCCN Guidelines Version 2.2020
Antiemesis

NCCN Guidelines Index
Table of Contents
Discussion

Clinical Trials: NCCN believes that the best management for any patient with cancer is in a clinical trial.
Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, click here: nccn.org/clinical_trials/member_institutions.aspx.

NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise indicated.

See NCCN Categories of Evidence and Consensus.

National Comprehensive Cancer Network®

NCCN Guidelines Version 2.2020
Antiemesis

NCCN Guidelines Index
Table of Contents
Discussion

Updates in Version 2.2020 of the NCCN Guidelines for Antiemesis from Version 1.2020 include:

Discussion

- **The Discussion section has been updated to reflect the changes in the algorithm.**

Updates in Version 1.2020 of the NCCN Guidelines for Antiemesis from Version 2.2019 include:

AE-1

- **4th bullet - Choice of antiemetic(s) used should be based on the emetic risk of the therapy, prior experience with antiemetics, and patient factors, added the following sub-bullets:**
  - ***Patient risk factors for anticancer-agent induced nausea/vomiting include:***
    - ◊ ***Younger age***
    - ◊ ***Female sex***
    - ◊ ***Previous history of CINV***
    - ◊ ***Little or no previous alcohol use***
    - ◊ ***Prone to motion sickness***
    - ◊ ***History of morning sickness during pregnancy***
    - ◊ ***Anxiety / high pretreatment expectation of nausea***
- **Added a new bullet: Antiemetic regimens added to a patient's anticancer agents may have a potential risk for drug-drug interactions. However, no clinically significant drug-drug interactions have emerged to date in randomized clinical trials of anticancer agents with antiemetics. The panel feels given a short duration of use (< 4 days; not chronic use) of these prophylactic antiemetic regimens; they would not result in clinically relevant interactions with anticancer agents. However, in all situations where medications are prescribed, clinicians must balance the benefit and risk for each patient.**

AE-2

- **Added a new footnote: The emetic risk is expected to be the same for biosimilars as for the parent compound unless otherwise noted.**
- **Moderate emetic risk anticancer agents, added:**
  - **Enfortumab vedotin-ejfv**
  - **Fam-Trastuzumab deruxtecan**

AE-3

- **Low emetic risk anticancer agents, added:**
  - **Arsenic trioxide (previously listed as moderate)**
  - **Mogamulizumab**
  - **Moxetumomab**
  - **Polatuzumab vedotin**
  - **Tagraxofusp**
- **Minimal emetic risk anticancer agents, added:**
  - **Cemiplimab**
  - **Trastuzumab/hyaluronidase**
- **Removed footnote: Corticosteroid antiemetic premedication should be avoided with immune checkpoint inhibitors when administered without cytotoxic chemotherapy. When immune checkpoint inhibitors are administered concurrently with emetogenic chemotherapy, inconclusive data suggest concurrent corticosteroid administration may negatively impact cancer outcomes. Until more evidence is available, the panel recommends employment of a corticosteroid-sparing approach to antiemetic prophylaxis on a case-by-case and regimen basis.**

AE-4

- **High emetic risk parenteral anticancer agents – acute and delayed emesis prevention – changed treatment option A to the preferred option.**

AE-4, AE-5, and AE-7

- **Replaced "chemotherapy" with "anticancer agents" in the page header.**
- **Removed "(order does not imply preference)."**
- **Added "treatment option" before the list of combinations for clarification.**

AE-5

- **Removed: ~~Note - An NK1 RA should be added (to dexamethasone and a 5-HT3 RA regimen) for select patients with additional risk factors or previous treatment failure with a corticosteroid + 5-HT3 RA alone~~. from treatment option F from the table and included as a revised footnote.**

National Comprehensive Cancer Network®

NCCN Guidelines Version 2.2020
Antiemesis

NCCN Guidelines Index
Table of Contents
Discussion

Updates in Version 1.2020 of the NCCN Guidelines for Antiemesis from Version 2.2019 include:

AE-6

- Modified footnote: *If not used previously,* consider escalating to this option (A) when emesis occurred during a previous cycle of chemotherapy using an olanzapine regimen (B, E) or an NK1 RA-containing regimen (C, D, or F). See Principles for Managing Breakthrough Emesis (AE-C).
- Modified footnote: Use of corticosteroid premedications should be avoided with cellular therapies. ~~And immune checkpoint inhibitors if at all possible.~~ See Pharmacologic Considerations for Antiemetic Prescribing (AE-B).
- Deleted footnote: Combination of olanzapine, aprepitant or fosaprepitant, any 5-HT3 RA, and dexamethasone, was studied in patients receiving cisplatin or AC. See Discussion.
- Modified footnote: No further 5-HT3 therapy required if palonosetron or granisetron extended release injection *administered, or if granisetron transdermal patch applied,* on day 1.
- Added a new footnote: A 3-drug prophylactic regimen (E or F) is recommended for select patients with additional patient-related risk factors (See AE-1) or previous treatment failure with a corticosteroid + 5-HT3 RA alone.

AE-8

- Moderate to high emetic risk agents, added:
  - Avapritinib
  - Binimetinib (previously listed as minimal)
  - Encorafenib (previously listed as minimal)
  - Selinexor
- Minimal to low emetic risk agents, added:
  - Alpelisib
  - Entrectinib
  - Erdafitinib
  - Trifluridine/tipiracil (previously listed as moderate)
  - Zanubrutinib

AE-10

- Removed "(order does not imply preference)" from top of treatmemt list.
- Modified: olanzapine 5–10 mg PO daily (*preferred*, category 1)

AE-B (1 of 2)

- 5-HT3 RAs, modified: ~~Depending on the route of administration and dose, 5-HT3 RA may increase the risk of developing prolongation of the QT interval of the electrocardiogram (ECG).a The palonosetron, granisetron extended-release injection, and granisetron transdermal patch drug package inserts do not contain this warning.~~ *The FDA recommends a maximum of 16 mg for a single dose of intravenous ondansetron to prevent prolongation of the QT interval of the ECG.* Dolasetron may increase the QT interval in a dose-dependent fashion.
- Corticosteroids, removed:
  - The use of corticosteroids as an antiemetic is not recommended with immunotherapies and cellular therapies.
  - Corticosteroid antiemetic premedication should be avoided with immune checkpoint inhibitors when administered without cytotoxic chemotherapy. When immune checkpoint inhibitors are administered concurrently with emetogenic chemotherapy, inconclusive data suggest concurrent corticosteroid administration may negatively impact cancer outcomes. Until more evidence is available, the panel recommends use of a corticosteroid-sparing approach to antiemetic prophylaxis on a case-by-case and regimen basis.
- Corticosteroids, modified: Corticosteroid antiemetic premedication should be avoided for 3–5 days prior to and 90 days after CAR T-cell therapies. ~~Antiemetic regimens used during lymphodepleting chemotherapy regimens should also use a corticosteroid-sparing approach to antiemetic prophylaxis.~~
- Olanzapine, removed:
  - Use caution when prescribing olanzapine with metoclopramide or haloperidol, as excessive dopamine blockade can increased the risk of extrapyramidal symptoms (EPS). Use of intermittent phenothiazine antiemetics (prochlorperazine or promethazine) for breakthrough CINV was safe in randomized clinical trials investigating the use of olanzapine but should be used with caution.
  - Olanzapine May increase the risk of developing prolongation of the QT interval of the ECG.
  - Intramuscular olanzapine use with concomitant parenteral benzodiazepine use is contraindicated. Toxicity may occur with this combination regardless of the route of administration. For olanzapine-containing regimens, use only PO lorazepam if needed.
  - Monitor for dystonic reactions.

UPDATES

Updates in Version 1.2020 of the NCCN Guidelines for Antiemesis from Version 2.2019 include:

- **Olanzapine, modified: CNS depression; use olanzapine with caution *or consider a lower dose* in patients at risk for falls (eg, elderly, debilitated, frail) or at risk for orthostatic hypotension.**
- **Olanzapine, added:**
  - **Consider 2.5 mg of olanzapine if patients report excessive sedation with 5 mg dose.**
  - **Consider administration at bedtime due to sedation.**

AE-B (2 of 2)

- **Benzodiazepines, removed: ~~I~~ntramuscular olanzapine use with concomitant parenteral benzodiazepine use is contraindicated. Toxicity may occur with this combination regardless of the route of administration. For olanzapine-containing regimens, use only PO lorazepam if needed.**
- **Benzodiazepines, modified: Use caution in patients *receiving* ~~with scheduled~~ opioids *due to increased risk of respiratory depression*.**
- **Phenothiazines, removed: The concomitant prescribing of any combination of prochlorperazine, promethazine, metoclopramide, or haloperidol should be used with caution, as excessive dopamine blockade can increase the risk of EPS.**
- **Removed footnote: Use caution and monitor ECG in patients with other risk factors for QT prolongation.**
- **Modified footnote: Use diphenhydramine 25–50 mg PO/IV either every 4 or every 6 h for dystonic reactions. If allergic to diphenhydramine, use benztropine at 1–2 mg IV or IM x 1 dose, followed by oral dose of 1–2 mg daily or BID if needed. *May consider using amantadine 100 mg BID-TID as treatment of drug-induced dystonic reactions for those patients intolerant of anticholinergic medications.***
- **Metoclopramide, removed: Avoid concomitant prescribing with olanzapine, the phenothiazines, or haloperidol, as excessive dopamine blockade can increase the risk of EPS.**
- **Metoclopramide, modified:**
  - **Use caution in patients at risk for falls (eg, elderly, debilitated, frail) ~~given the increased risk for EPS~~.**
  - ***May increase the QT interval of the ECG*** **~~monitor for QT prolongationa~~**
  - **Clinical pearl: Metoclopramide increases gut motility ~~and may cause diarrhea~~ and can be utilized to ~~help~~ manage gastroparesis.**
- **Haloperidol, removed:**
  - **Avoid concomitant prescribing with olanzapine, the phenothiazines, or metoclopramide, as excessive dopamine blockade can increase the risk of EPS.**
  - **Monitor for QT prolongation.a Higher-than-recommended doses (regardless of route) and intravenous administration of haloperidol appear to be associated with a higher risk of QT prolongation.**
- **Haloperidol, added: *May increase the QT interval of the ECG***
- **Cannabinoid, modified:**
  - **CNS depression; use caution in patients at risk for falls (eg, elderly, debilitated, frail)~~, at risk for dependence or orthostatic hypotension, or with underlying psychiatric disorders~~.**
  - **Clinical pearl: May stimulate appetite. To minimize *adverse effects* ~~paranoia/hallucinations~~, consider starting with lower doses (especially in elderly or marijuana-naïve patients) and titrate ~~upwards~~ to effect ~~as clinically appropriate~~.**

PRINCIPLES OF EMESIS CONTROL FOR THE CANCER PATIENT

- Prevention of nausea/vomiting is the goal.
  - The risk of nausea/vomiting (acute ≤24 hours vs. delayed nausea >24 hours) for persons receiving chemotherapy of high and moderate emetic risk lasts for at least 3 days for high and 2 days for moderate after the last dose of chemotherapy. Patients need to be protected throughout the full period of risk.
- Oral and parenteral serotonin receptor antagonists (5-HT3 RA) have equivalent efficacy when used at the appropriate doses and intervals.
- Consider the toxicity of the specific antiemetic(s). See Pharmacologic Considerations for Antiemetic Prescribing (AE-B).
- Choice of antiemetic(s) used should be based on the emetic risk of the therapy, prior experience with antiemetics, and patient factors.
  - Patient risk factors for anticancer-agent induced nausea/vomiting include:
    - ◊ Younger age
    - ◊ Female sex
    - ◊ Previous history of CINV
    - ◊ Little or no previous alcohol use
    - ◊ Prone to motion sickness
    - ◊ History of morning sickness during pregnancy
    - ◊ Anxiety / high pretreatment expectation of nausea
- There are other potential causes of emesis in patients with cancer. These may include:
  - Partial or complete bowel obstruction
  - Vestibular dysfunction
  - Brain metastases
  - Electrolyte imbalance: hypercalcemia, hyperglycemia, or hyponatremia
  - Uremia
  - Concomitant drug treatments, including opioids
  - Gastroparesis: tumor or chemotherapy (eg, vincristine) induced or other causes (eg, diabetes)
  - Excessive secretions (eg, seen in patients with head and neck cancers)
  - Malignant ascites
  - Psychophysiologic:
    - ◊ Anxiety
    - ◊ Anticipatory nausea/vomiting
- For use of antiemetics for nausea/vomiting that are not related to radiation and/or chemotherapy, see NCCN Guidelines for Palliative Care.
- For multi-drug regimens, select antiemetic therapy based on the drug with the highest emetic risk. See Emetogenic Potential of Parenteral Anticancer Agents (AE-2 and AE-3), and see Emetogenic Potential of Oral Anticancer Agents (AE-8).
- Antiemetic regimens added to a patient's anticancer agents may have a potential risk for drug-drug interactions. However, no clinically significant drug-drug interactions have emerged to date in randomized clinical trials of anticancer agents with antiemetics. The panel feels given a short duration of use (< 4 days; not chronic use) of these prophylactic antiemetic regimens; they would not result in clinically relevant interactions with anticancer agents. However, in all situations where medications are prescribed, clinicians must balance the benefit and risk for each patient.
- Consider using an H2 blocker or proton pump inhibitor to prevent dyspepsia, which can mimic nausea.
- Lifestyle measures may help to alleviate nausea/vomiting, such as eating small frequent meals, choosing healthful foods, controlling the amount of food consumed, and eating food at room temperature. A dietary consult may also be useful. See NCI's "Eating Hints: Before, During, and After Cancer Treatment." (http://www.cancer.gov/cancertopics/coping/eatinghints/page2#4)
- While anticancer agents or radiation therapy-induced nausea and vomiting can significantly impact a patient's quality of life and lead to poor outcomes, providers must be aware of the potential for the overuse of prophylactic antiemetics, especially for chemotherapy with minimal and low emetic risks, which may expose the patient to potential adverse effects from antiemetic drugs and pose an undue economic burden. Guideline adherence is always encouraged.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

EMETOGENIC POTENTIAL OF PARENTERAL ANTICANCER AGENTS[a]

LEVEL	AGENT		
High emetic risk (>90% frequency of emesis)[b,c,d]	• AC combination defined as any chemotherapy regimen that contains an anthracycline and cyclophosphamide • Carboplatin AUC ≥4	• Carmustine >250 mg/m² • Cisplatin • Cyclophosphamide >1,500 mg/m² • Dacarbazine • Doxorubicin ≥60 mg/m²	• Epirubicin >90 mg/m² • Ifosfamide ≥2 g/m² per dose • Mechlorethamine • Streptozocin
Moderate emetic risk (>30%–90% frequency of emesis)[b,c,d]	• Aldesleukin >12–15 million IU/m² • Amifostine >300 mg/m² • Azacitidine • Bendamustine • Busulfan • Carboplatin AUC[e] <4 • Carmustine[e] ≤250 mg/m² • Clofarabine • Cyclophosphamide[e] ≤1500 mg/m² • Cytarabine >200 mg/m² • Dactinomycin[e]	• Daunorubicin[e] • Dual-drug liposomal encapsulation of cytarabine and daunorubicin • Dinutuximab • Doxorubicin[e] <60 mg/m² • Enfortumab vedotin-ejfv • Epirubicin[e] ≤90 mg/m² • Fam-trastuzumab deruxtecan • Idarubicin[e] • Ifosfamide[e] <2 g/m² per dose • Interferon alfa ≥10 million IU/m²	• Irinotecan[e] • Irinotecan (liposomal) • Melphalan • Methotrexate[e] ≥250 mg/m² • Oxaliplatin[e] • Temozolomide • Trabectedin[e]

Adapted with permission from:
Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-109.
Grunberg SM, Warr D, Gralla RJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art. Support Care Cancer 2011;19:S43-S47.

[a] Potential drug interactions between antineoplastic agents/antiemetic agents and various other drugs should always be considered.
[b] Proportion of patients who experience emesis in the absence of effective antiemetic prophylaxis.
[c] Continuous infusion may make an agent less emetogenic.
[d] The emetic risk is expected to be the same for biosimilars as for the parent compound unless otherwise noted.
[e] These agents may be highly emetogenic in certain patients.

Low Emetic Risk (See AE-3)
Minimal Emetic Risk (See AE-3)
Oral Chemotherapy (See AE-8)

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

EMETOGENIC POTENTIAL OF PARENTERAL ANTICANCER AGENTS[a]

LEVEL	AGENT			
Low emetic risk (10%–30% frequency of emesis)[b,d,f]	• Ado-trastuzumab emtansine • Aldesleukin ≤12 million IU/m² • Amifostine ≤300 mg/m² • Arsenic trioxide • Axicabtagene ciloleucel[g] • Belinostat • Brentuximab vedotin • Cabazitaxel • Carfilzomib • Copanlisib	• Cytarabine (low dose) 100–200 mg/m² • Docetaxel • Doxorubicin (liposomal) • Eribulin • Etoposide • 5-Fluorouracil (5-FU) • Floxuridine • Gemcitabine • Gemtuzumab ozogamicin • Inotuzumab ozogamicin • Ixabepilone	• Methotrexate >50 mg/m² - <250 mg/m² • Mitomycin • Mitoxantrone • Mogamulizumab • Moxetumomab • Necitumumab • Olaratumab • Omacetaxine • Paclitaxel • Paclitaxel-albumin	• Pemetrexed • Pentostatin • Polatuzumab vedotin • Pralatrexate • Romidepsin • Tagraxofusp • Talimogene laherparepvec • Thiotepa • Tisagenlecleucel[g] • Topotecan • Ziv-aflibercept
Minimal emetic risk (<10% frequency of emesis)[b,d,f]	• Alemtuzumab • Atezolizumab • Avelumab • Asparaginase • Bevacizumab • Bleomycin • Blinatumomab • Bortezomib • Cetuximab • Cemiplimab • Cladribine • Cytarabine <100 mg/m² • Daratumumab	• Decitabine • Denileukin diftitox • Dexrazoxane • Durvalumab • Elotuzumab • Fludarabine • Ipilimumab • Methotrexate ≤50 mg/m² • Nelarabine • Nivolumab	• Obinutuzumab • Ofatumumab • Panitumumab • Pegaspargase • Peginterferon • Pembrolizumab • Pertuzumab • Ramucirumab • Rituximab • Rituximab and hyaluronidase human injection, for subcutaneous use	• Siltuximab • Temsirolimus • Trastuzumab • Trastuzumab and hyaluronidase injection, for subcutaneous use • Valrubicin • Vinblastine • Vincristine • Vincristine (liposomal) • Vinorelbine

Adapted with permission from: Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-109.
Grunberg SM, Warr D, Gralla RJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art. Support Care Cancer 2011;19:S43-S47.

[a] Potential drug interactions between antineoplastic agents/antiemetic agents and various other drugs should always be considered.
[b] Proportion of patients who experience emesis in the absence of effective antiemetic prophylaxis.
[d] The emetic risk is expected to be the same for biosimilars as for the parent compound unless otherwise noted.
[f] For some low emetic risk agents, factors related to dosing schedule (particularly continuous dosing) and clinical experience suggest routine premedication is not required. An individualized approach is appropriate for whether to premedicate each dose or prescribe antiemetics as needed.
[g] Corticosteroid antiemetic premedication should be avoided for 3–5 days prior to and 90 days after CAR T-cell therapies. Antiemetic regimens used during lymphodepleting chemotherapy regimens should also employ a corticosteroid-sparing approach to antiemetic prophylaxis.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

HIGH EMETIC RISK PARENTERAL ANTICANCER AGENTS — ACUTE AND DELAYED EMESIS PREVENTION[h,i,j,k,l]

DAY 1: Select treatment option A, B, or C All treatment options are category 1 and should be started before chemotherapy[j]	DAYS 2, 3, 4:
Treatment option A (preferred), use the following combination: • Olanzapine 5–10 mg PO once[m,n] • NK1 RA (choose one): ▸ Aprepitant 125 mg PO once ▸ Aprepitant injectable emulsion 130 mg IV once[o] ▸ Fosaprepitant 150 mg IV once ▸ Netupitant 300 mg / palonosetron 0.5 mg (available as fixed combination product only) PO once[p] ▸ Fosnetupitant 235 mg / palonosetron 0.25 mg (available as fixed combination product only) IV once[p] ▸ Rolapitant 180 mg PO once[q] • 5-HT3 RA (choose one):[r,s] ▸ Dolasetron 100 mg PO once ▸ Granisetron 10 mg SQ once,[t] or 2 mg PO once, or 0.01 mg/kg (max 1 mg) IV once, or 3.1 mg/24-h transdermal patch applied 24–48 h prior to first dose of chemotherapy. ▸ Ondansetron 16–24 mg PO once, or 8–16 mg IV once ▸ Palonosetron 0.25 mg IV once • Dexamethasone 12 mg PO/IV once[u,v]	**Treatment option A:** • Olanzapine 5–10 mg PO daily on days 2, 3, 4[m] • Aprepitant 80 mg PO daily on days 2, 3 (if aprepitant PO used on day 1) • Dexamethasone 8 mg[u,v] PO/IV daily on days 2, 3, 4
Treatment option B, use the following combination: • Olanzapine 5–10 mg PO once[m] • Palonosetron 0.25 mg IV once • Dexamethasone 12 mg PO/IV once[u,v]	**Treatment option B:** • Olanzapine 5–10 mg PO daily on days 2, 3, 4[m]
Treatment option C, use the following combination: • NK1 RA (choose one): ▸ Aprepitant 125 mg PO once ▸ Aprepitant injectable emulsion 130 mg IV once[o] ▸ Fosaprepitant 150 mg IV once ▸ Netupitant 300 mg / palonosetron 0.5 mg (available as fixed combination product only) PO once[p] ▸ Fosnetupitant 235 mg / palonosetron 0.25 mg (available as fixed combination product only) IV once[p] ▸ Rolapitant 180 mg PO once[q] • 5-HT3 RA (choose one):[r,s] ▸ Dolasetron 100 mg PO once ▸ Granisetron 10 mg SQ once,[t] or 2 mg PO once, or 0.01 mg/kg (max 1 mg) IV once, or 3.1 mg/24-h transdermal patch applied 24–48 h prior to first dose of chemotherapy. ▸ Ondansetron 16–24 mg PO once, or 8–16 mg IV once ▸ Palonosetron 0.25 mg IV once • Dexamethasone 12 mg PO/IV once[u,v]	**Treatment option C:** • Aprepitant 80 mg PO daily on days 2, 3 (if aprepitant PO used on day 1) • Dexamethasone 8 mg[u,v] PO/IV daily on days 2, 3, 4

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

Footnotes

MODERATE EMETIC RISK PARENTERAL ANTICANCER AGENTS — ACUTE AND DELAYED EMESIS PREVENTION[h,i,j,k,l]

DAY 1: Select treatment option D, E, or F. All treatment options are category 1 and should be started before chemotherapy:[j]	DAYS 2, 3:
Treatment option D, use the following combination: • 5-HT3 RA (choose one): ▸ Dolasetron 100 mg PO once ▸ Granisetron 10 mg SQ once[t] (preferred), or 2 mg PO once, or 0.01 mg/kg (max 1 mg) IV once, or 3.1 mg/24-h transdermal patch applied 24–48 h prior to first dose of chemotherapy. ▸ Ondansetron 16–24 mg PO once, or 8–16 mg IV once ▸ Palonosetron 0.25 mg IV once (preferred) • Dexamethasone 12 mg PO/IV once[u,v]	Treatment option D: • Dexamethasone 8 mg[u,v] PO/IV daily on days 2, 3 OR • 5-HT3 RA monotherapy[w]: ▸ Granisetron 1–2 mg (total dose) PO daily or 0.01 mg/kg (max 1 mg) IV daily on days 2 and 3 ▸ Ondansetron 8 mg PO twice daily or 16 mg PO daily or 8–16 mg IV daily on days 2, 3 ▸ Dolasetron 100 mg PO daily on days 2, 3
Treatment option E, use the following combination:[x] • Olanzapine 5–10 mg PO once[m] • Palonosetron 0.25 mg IV once • Dexamethasone 12 mg PO/IV once[u,v]	Treatment option E: • Olanzapine 5–10 mg PO daily on days 2, 3[m]
Treatment option F, use the following combination:[x] • NK1 RA (choose one): ▸ Aprepitant 125 mg PO once ▸ Aprepitant injectable emulsion 130 mg IV once[o] ▸ Fosaprepitant 150 mg IV once[p] ▸ Netupitant 300 mg / palonosetron 0.5 mg (available as fixed combination product only) PO once[p] ▸ Fosnetupitant 235 mg / palonosetron 0.25 mg (available as fixed combination product only) IV once[p] ▸ Rolapitant 180 mg PO once[q] • 5-HT3 RA (choose one):[r,s] ▸ Dolasetron 100 mg PO once ▸ Granisetron 10 mg SQ once,[t] or 2 mg PO once, or 0.01 mg/kg (max 1 mg) IV once, or 3.1 mg/24-h transdermal patch applied 24–48 h prior to first dose of chemotherapy. ▸ Ondansetron 16–24 mg PO once, or 8–16 mg IV once ▸ Palonosetron 0.25 mg IV once • Dexamethasone 12 mg PO/IV once[u,v]	Treatment option F: • Aprepitant 80 mg PO daily on days 2, 3 (if aprepitant PO used on day 1) • ± Dexamethasone 8 mg[u,v] PO/IV daily on days 2, 3

Footnotes

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

Footnotes for pages AE-4 and AE-5

[h] See Emetogenic Potential of Parenteral Anticancer Agents (AE-2).
[i] Antiemetic regimens should be chosen based on the drug with the highest emetic risk as well as patient-specific risk factors.
[j] See Principles of Managing Multiday Emetogenic Chemotherapy Regimens (AE-A).
[k] With or without lorazepam 0.5–2 mg PO or IV or sublingual every 6 hours as needed days 1–4. With or without H2 blocker or proton pump inhibitor. For olanzapine-containing regimens, only use PO lorazepam if needed. See Principles of Emesis Control for the Cancer Patient (AE-1).
[l] See Pharmacologic Considerations for Antiemetic Prescribing (AE-B).
[m] Emerging data from smaller studies and clinical practice suggest a 5 mg dose may be considered, especially for elderly or oversedated patients. See Pharmacologic Considerations for Antiemetic Prescribing (AE-B).
[n] If not used previously, consider escalating to this option (A) when emesis occurred during a previous cycle of chemotherapy using an olanzapine regimen (B, E) or an NK1 RA-containing regimen (C, D, or F). See Principles for Managing Breakthrough Emesis (AE-C).
[o] Aprepitant injectable emulsion is a unique formulation of aprepitant and is NOT interchangeable with the intravenous formulation of fosaprepitant.
[p] Available as a fixed combination product only.
[q] Rolapitant has an extended half-life and should not be administered at less than 2-week intervals.
[r] If netupitant/palonosetron or fosnetupitant/palonosetron fixed combination product used, no further 5-HT3 RA is required.
[s] When used in combination with an NK1 RA, there is no preferred 5-HT3 RA. See Principles of Managing Multiday Emetogenic Chemotherapy Regimens (AE-A).
[t] Granisetron extended-release injection is a unique formulation of granisetron using a polymer-based drug delivery system. This formulation is specifically intended for subcutaneous administration and is NOT interchangeable with the intravenous formulation. Granisetron extended-release injection has an extended half-life and should not be administered at less than 1-week intervals.
[u] Emerging data and clinical practice suggest dexamethasone doses may be individualized. Higher doses may be considered, especially when an NK1 RA is not given concomitantly. Lower doses, given for shorter durations, or even elimination of dexamethasone on subsequent days (for delayed nausea and emesis prevention) may be acceptable for non-cisplatin regimens based on patient characteristics. If dexamethasone eliminated on subsequent days for delayed nausea and emesis prevention, consider other alternative antiemetics (eg, olanzapine). See Discussion.
[v] Use of corticosteroid premedications should be avoided with cellular therapies. See Pharmacologic Considerations for Antiemetic Prescribing (AE-B).
[w] No further 5-HT3 therapy required if palonosetron or granisetron extended-release injection administered, or if granisetron transdermal patch applied, on day 1.
[x] A 3-drug prophylactic regimen (E or F) is recommended for select patients with additional patient-related risk factors (See AE-1) or previous treatment failure with a corticosteroid + 5-HT3 RA alone.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

LOW AND MINIMAL EMETIC RISK PARENTERAL ANTICANCER AGENTS - EMESIS PREVENTION[h,i,j,l]

Low →

Start before chemotherapy[i,j,y]
Repeat daily for multiday doses of chemotherapy
- **Dexamethasone 8–12 mg PO/IV once[l,y]**
  or
- **Metoclopramide 10–20 mg PO/IV once[l,y]**
  or
- **Prochlorperazine 10 mg PO/IV once[l,y]**
  or
- **5-HT3 RA[l,y] (select one):**
  - ◊ **Dolasetron 100 mg PO once**
  - ◊ **Granisetron 1–2 mg (total dose) PO once**
  - ◊ **Ondansetron 8–16 mg PO once**

→ Breakthrough Treatment for Chemotherapy-Induced Nausea/Vomiting (AE-10)

Minimal → **No routine prophylaxis** →

[h] See Emetogenic Potential of Parenteral Anticancer Agents (AE-3).
[i] Antiemetic regimens should be chosen based on the drug with the highest emetic risk as well as patient-specific risk factors.
[j] See Principles of Managing Multiday Emetogenic Chemotherapy Regimens (AE-A).
[l] See Pharmacologic Considerations for Antiemetic Prescribing (AE-B).
[y] With or without lorazepam 0.5–2 mg PO or IV or sublingual every 6 hours as needed days 1–4. With or without H2 blocker or proton pump inhibitor. See Principles of Emesis Control for the Cancer Patient (AE-1).

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

EMETOGENIC POTENTIAL OF ORAL ANTICANCER AGENTS[a]

LEVEL	AGENT			
Moderate to high emetic risk[b,z] (≥30% frequency of emesis)	• Altretamine • Avapritinib • Binimetinib • Busulfan (≥4 mg/d) • Ceritinib • Crizotinib	• Cyclophosphamide (≥100 mg/m²/day) • Dabrafenib • Enasidenib • Encorafenib • Estramustine	• Etoposide • Lenvatinib • Lomustine (single day) • Midostaurin • Mitotane	• Niraparib • Olaparib • Procarbazine • Rucaparib • Selinexor • Temozolomide (>75 mg/m²/day)
Minimal to low emetic risk[b] (<30% frequency of emesis)	• Abemaciclib • Acalabrutinib • Afatinib • Alectinib • Alpelisib • Axitinib • Bexarotene • Brigatinib • Bosutinib • Busulfan (<4 mg/day) • Cabozantinib • Capecitabine • Chlorambucil • Cobimetinib • Cyclophosphamide (<100 mg/m²/day) • Dacomitinib • Dasatinib	• Duvelisib • Entrectinib • Erdafitinib • Erlotinib • Everolimus • Fludarabine • Gefitinib • Gilteritinib • Glasdegib • Hydroxyurea • Ibrutinib • Idelalisib • Imatinib • Ixazomib • Ivosidenib • Lapatinib • Larotrectinib • Lenalidomide	• Lorlatinib • Melphalan • Mercaptopurine • Methotrexate • Nilotinib • Neratinib • Osimertinib • Palbociclib • Panobinostat • Pazopanib • Pomalidomide • Ponatinib • Regorafenib • Ribociclib • Ruxolitinib • Sonidegib • Sorafenib	• Sunitinib • Talazoparib tosylate • Temozolomide (≤75 mg/m²/day)[aa] • Thalidomide • Thioguanine • Topotecan • Trametinib • Tretinoin • Trifluridine/tipiracil • Vandetanib • Vemurafenib • Venetoclax • Vismodegib • Vorinostat • Zanubrutinib

Adapted with permission from:
Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-109.
Grunberg SM, Warr D, Gralla RJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-state of the art. Support Care Cancer 2011;19:S43-S47.

[a] Potential drug interactions between antineoplastic agents/antiemetic agents and various other drugs should always be considered.
[b] Proportion of patients who experience emesis in the absence of effective antiemetic prophylaxis.
[z] For some moderate to high emetic risk agents, factors related to dosing schedule (particularly continuous dosing for prolonged periods), and clinical experience suggest routine premedication is not required. An individualized approach is appropriate for whether to premedicate each dose or prescribe antiemetics as needed.
[aa] Temozolomide ≤75 mg/m²/day should be considered moderately emetogenic with concurrent radiotherapy.

High Emetic Risk (See AE-2)
Moderate Emetic Risk (See AE-2)
Low Emetic Risk (See AE-3)
Minimal Emetic Risk (See AE-3)

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

ORAL CHEMOTHERAPY - EMESIS PREVENTION[i,j,bb,cc]

High to moderate emetic risk →

Start before chemotherapy and continue daily (order does not imply preference)[y]
- **5-HT3 RA (choose one):[l]**
  - **Dolasetron 100 mg PO daily**
  - **Granisetron 1–2 mg (total dose) PO daily or 3.1 mg/24-h transdermal patch every 7 days**
  - **Ondansetron 8–16 mg (total dose) PO daily**

→ **Breakthrough Treatment for Chemotherapy-Induced Nausea/Vomiting (AE-10)**

Low to minimal emetic risk → **PRN recommended** → **Nausea/ vomiting** →

Start before chemotherapy and continue daily (order does not imply preference)[y]
- **Metoclopramide 10–20 mg PO and then every 6 h PRN[l]**
  or
- **Prochlorperazine 10 mg PO and then every 6 h PRN (maximum 40 mg/day)[l]**
  or
- **5-HT3 RA (choose one):[l]**
  - ◊ **Dolasetron 100 mg PO daily PRN**
  - ◊ **Granisetron 1–2 mg (total dose) PO daily PRN**
  - ◊ **Ondansetron 8–16 mg (total dose) PO daily PRN**

→ **Breakthrough Treatment for Chemotherapy-Induced Nausea/Vomiting (AE-10)**
and
Consider changing antiemetic therapy to higher level primary therapy for the next cycle

[i] Antiemetic regimens should be chosen based on the drug with the highest emetic risk as well as patient-specific risk factors.
[j] See Principles of Managing Multiday Emetogenic Chemotherapy Regimens (AE-A).
[l] See Pharmacologic Considerations for Antiemetic Prescribing (AE-B).
[y] With or without lorazepam 0.5–2 mg PO or IV or sublingual every 6 hours as needed days 1–4. With or without H2 blocker or proton pump inhibitor. See Principles of Emesis Control for the Cancer Patient (AE-1).
[bb] See Emetogenic Potential of Oral Anticancer Agents (AE-8).
[cc] These antiemetic recommendations apply to oral chemotherapy only. When combined with IV agents in a combination chemotherapy regimen, the antiemetic recommendations for the agent with the highest level of emetogenicity should be followed. If multiple oral agents are combined, emetic risk may increase and require prophylaxis.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

BREAKTHROUGH TREATMENT FOR CHEMOTHERAPY-INDUCED NAUSEA/VOMITING[j,dd]

Any nausea/ vomiting

The general principle of breakthrough treatment is to add one agent from a different drug class to the current regimen.

Atypical antipsychotic:[l]
- **Olanzapine 5–10 mg PO daily (preferred, category 1)[ee,ff]**

• Benzodiazepine:[l]
- **Lorazepam 0.5–2 mg PO/SL/IV every 6 h[ff]**

• Cannabinoid:[l]
- **Dronabinol capsules 5–10 mg, or dronabinol oral solution 2.1–4.2 mg/m², PO 3–4 times daily[gg]**
- **Nabilone 1–2 mg PO BID**

• Other:
- **Haloperidol 0.5–2 mg PO/IV every 4–6 h[l]**
- **Metoclopramide 10–20 mg PO/IV every 4–6 h[l]**
- **Scopolamine 1.5 mg transdermal patch 1 patch every 72 h**

• Phenothiazine:[l]
- **Prochlorperazine 25 mg supp PR every 12 h or 10 mg PO/IV every 6 h[l]**
- **Promethazine 25 mg supp PR every 6 h or 12.5–25 mg PO every 4–6 h[j]**

• 5-HT3 RA:[l]
- **Dolasetron 100 mg PO daily**
- **Granisetron 1–2 mg PO daily or 1 mg PO BID or 0.01 mg/kg (maximum 1 mg) IV daily or 3.1 mg/24-h transdermal patch every 7 days**
- **Ondansetron 16–24 mg PO daily or 8–16 mg IV**

• Corticosteroid:[l]
- **Dexamethasone 12 mg PO/IV daily**

RESPONSE

Nausea and vomiting controlled → **Continue breakthrough medications, on a schedule, not PRN**

Nausea and/ or vomiting uncontrolled → **Re-evaluate and consider dose adjustments and/ or sequentially add one agent from a different drug class**

SUBSEQUENT CYCLES

Consider changing antiemetic therapy to higher level primary treatment for next cycle

[j] See Principles of Managing Multiday Emetogenic Chemotherapy Regimens (AE-A).
[l] See Pharmacologic Considerations for Antiemetic Prescribing (AE-B).
[dd] See Principles for Managing Breakthrough Emesis (AE-C).

[ee] When not used as part of the acute and delayed emesis prevention regimen.
[ff] For olanzapine-containing regimens, only use PO lorazepam. See Principles of Emesis Control for the Cancer Patient (AE-1).
[gg] Dronabinol oral solution has greater oral bioavailability than dronabinol capsules; 2.1 mg oral solution = 2.5 mg capsules.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

RADIATION-INDUCED EMESIS PREVENTION/TREATMENT

EMETOGENIC POTENTIAL	TYPE OF RADIATION THERAPY	BREAKTHROUGH TREATMENT



[l] See Pharmacologic Considerations for Antiemetic Prescribing (AE-B).

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

ANTICIPATORY EMESIS PREVENTION/TREATMENT

Anticipatory nausea/vomiting →

- **Prevention is key:**
  - **Use optimal antiemetic therapy during every cycle of treatment**
  - **Avoid strong smells that may precipitate symptoms**
- **Behavioral therapy:**
  - **Relaxation/systematic desensitization**
  - **Hypnosis**
  - **Relaxation exercises**
    - ◊ **Guided imagery**
    - ◊ **Progressive muscle relaxation (PMR)**
    - ◊ **Biofeedback**
    - ◊ **Music therapy**
  - **Cognitive distraction**
  - **Yoga (if approved by physician)**
- **Acupuncture/acupressure**
- **Consider anxiolytic therapy:**
  - **For example, lorazepam 0.5–2 mg PO beginning on the night before treatment and then repeated the next day 1–2 hours before chemotherapy begins**

→ **See Emesis Prevention and Breakthrough Treatment for Chemotherapy-Induced Nausea and Vomiting (Antiemesis Table of Contents)**

See Principles of Emesis Control for the Cancer Patient (AE-1)

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

PRINCIPLES OF MANAGING MULTIDAY EMETOGENIC CHEMOTHERAPY REGIMENS[a]

Summary:

- **Patients receiving multiday chemotherapy are at risk for both acute and delayed nausea/vomiting based on the emetogenic potential of the individual chemotherapy agents administered on any given day and their sequence. It is therefore difficult to recommend a specific antiemetic regimen for each day, especially since acute and delayed emesis may overlap after the initial day of chemotherapy until the last day of chemotherapy.**
- **After chemotherapy administration concludes, the period of risk for delayed emesis also depends on the specific regimen and the emetogenic potential of the last chemotherapy agent administered in the regimen.**
- **Practical issues also need to be considered when designing the antiemetic regimen, taking into account the administration setting (eg, inpatient versus outpatient), preferred route of administration (parenteral, oral, or transdermal), duration of action of the 5-HT3 RA and appropriate associated dosing intervals, tolerability of daily antiemetics (eg, corticosteroids), adherence/compliance issues, and individual risk factors.**

General principles:

Corticosteroids:

- **Dexamethasone should be administered once daily (either orally or intravenously) for moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC), then continued for 2 to 3 days after chemotherapy for regimens that are likely to cause significant delayed emesis.**
- **Dexamethasone dose may be modified or omitted when the chemotherapy regimen already includes a corticosteroid.**
- **Dexamethasone-sparing strategies**
  - **For patients receiving MEC or non-cisplatin HEC, especially those patients with few identifiable chemotherapy-induced nausea and vomiting (CINV) risk factors or who are intolerant to corticosteroids, limiting the administration of dexamethasone to day 1 only is an option that may not be associated with a significant reduction in antiemetic control.[1-4]**
  - **If patients cannot tolerate dexamethasone, consider replacing with olanzapine.**

[a] The panel acknowledges that evidence is lacking to support every clinical scenario. Decisions should be individualized for each chemotherapy regimen and each patient. An extensive knowledge of the available clinical data, pharmacology, pharmacodynamics, and pharmacokinetics of the antiemetics and the chemotherapy and experience with patients (regarding tolerability and efficacy) are all paramount to successfully implementing these guidelines into clinical practice.

Continued

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

PRINCIPLES OF MANAGING MULTIDAY EMETOGENIC CHEMOTHERAPY REGIMENS[a]

Serotonin receptor antagonists (5-HT3 RA):

- A 5-HT3 RA should be administered prior to the first (and subsequent) doses of moderately or highly emetogenic chemotherapy. The frequency or need for repeated administration of the 5-HT3 RA depends on the agent chosen and its mode of administration (parenteral/oral/transdermal).
- Palonosetron:
  - A single intravenous palonosetron dose of 0.25 mg may be sufficient prior to the start of a 3-day chemotherapy regimen instead of multiple daily doses of another oral or intravenous 5-HT3 RA.
  - Repeat dosing of palonosetron 0.25 mg IV is likely to be safe, based on available evidence.
  - In terms of efficacy, limited data are available for multiday dosing.[5]
- Granisetron extended-release injection:
  - Granisetron extended-release injection is a unique formulation of granisetron using a polymer-based drug delivery system. This formulation is specifically intended for subcutaneous administration and is NOT interchangeable with the intravenous formulation. Granisetron extended-release injection has an extended half-life and should not be administered at less than 1-week intervals.
  - A single subcutaneous dose of 10 mg was found to be non-inferior to a single intravenous dose of palonosetron 0.25 mg for the prevention of acute and delayed CINV following MEC or HEC when both are used in combination with dexamethasone.[6]
  - A single subcutaneous dose of 10 mg was found to be superior to a single intravenous dose of ondansetron for the prevention of delayed CINV following HEC when both are used in combination with fosaprepitant and dexamethasone.[7]
- When palonosetron or granisetron extended-release injection is used as part of an antiemetic regimen that does NOT contain an NK1 RA, palonosetron or granisetron extended-release injection are the preferred 5-HT3 RA.[6,8]

Neurokinin-1 receptor antagonists (NK1 RA):

- NK1 RAs may be used for multiday chemotherapy regimens likely to be moderately or highly emetogenic and associated with significant risk for delayed nausea and emesis.
- For single-day chemotherapy regimens, category 1 evidence is available for aprepitant, aprepitant injectable emulsion, fosaprepitant, netupitant, fosnetupitant, or rolapitant administered in combination with a 5-HT3 RA and corticosteroid (see AE-5 and AE-6).
- If the oral aprepitant regimen is chosen, limited data exist to support administration of aprepitant on days 4 and 5 after multiday chemotherapy.
- Data from a small phase III randomized study support the use of aprepitant (125 mg day 3, 80 mg days 4–7) with 5-HT3 RA (days 1–5) and dexamethasone (20 mg days 1, 2) in patients with germline cancers treated with a 5-day cisplatin-based chemotherapy.[9]
- Studies investigating repeat dosing of aprepitant injectable emulsion, fosaprepitant, netupitant, fosnetupitant, and rolapitant are not available.
- Fosaprepitant, aprepitant, aprepitant injectable emulsion, netupitant, and fosnetupitant inhibit the metabolism of dexamethasone and may cause higher dexamethasone concentrations. Rolapitant does not inhibit dexamethasone metabolism.
- Rolapitant has an extended half-life and should not be administered at less than 2-week intervals.

[a] The panel acknowledges that evidence is lacking to support every clinical scenario. Decisions should be individualized for each chemotherapy regimen and each patient. An extensive knowledge of the available clinical data, pharmacology, pharmacodynamics, and pharmacokinetics of the antiemetics and the chemotherapy and experience with patients (regarding tolerability and efficacy) are all paramount to successfully implementing these guidelines into clinical practice.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

PRINCIPLES OF MANAGING MULTIDAY EMETOGENIC CHEMOTHERAPY REGIMENS

REFERENCES

[1] Matsuzaki K, Ito Y, Fukuda M, et al. Placebo-controlled phase III study comparing dexamethasone on day 1 to day 1-3 with NK1 receptor antagonist and palonosetron in high emetogenic chemotherapy. J Clin Oncol 2016;34: Abstract 10019.
[2] Rolia F, Ruggeri B, Ballatori E, et al. Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: A randomized double-blind study. J Clin Oncol 2014;32:101-106.
[3] Aapro M, Fabi A, Nole F, et al. Double-blind, randomized, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 2010;21(5):1083-1088.
[4] Celio L, Bonizzoni E, Bajetta E, et al. Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials. Support Care Cancer 2013;21(2):565-573.
[5] Giralt SA, Mangan KF, Maziarz RT, et al. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Ann Oncol 2011;22:939-946.
[6] Raftopoulos H, Cooper W, O'Boyle E, et al. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial. Support Care Cancer 2015 ;23(3):723-732.
[7] Schnadig ID, Agajanian R, Dakhil C, et al. APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy. Future Oncol 2016;12:1469-1481.
[8] Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009;10(2):115-124.
[9] Albany C, Brames MJ, Fausel C, et al. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study. J Clin Oncol 2012;30:3998-4003.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

PHARMACOLOGIC CONSIDERATIONS FOR ANTIEMETIC PRESCRIBING (In Order as the Drugs Appear in the Guideline)

To ensure safe and effective treatment with antiemetic therapy, develop a treatment plan with the patient that includes medication access, screening of concomitant medications, goals of therapy, instructions for proper use and side effect management, and adherence assessment. Many of the antiemetic agents contained within this guideline have multiple potential drug-drug or drug-disease interactions. Review patient medical profile and drug package insert for specific interactions and recommendations.

NK1 RAs:
- **Aprepitant, aprepitant injectable emulsion, fosaprepitant, netupitant, and fosnetupitant inhibit the metabolism of dexamethasone, thus increasing dexamethasone serum levels when administered concomitantly. Rolapitant does not share this interaction with dexamethasone.**
- **Rolapitant has an extended half-life and should not be administered at less than 2-week intervals.**
- **Clinical pearl: Place in therapy is for prevention of CINV, not treatment of CINV. Largest benefit seen in delayed CINV setting.**

5-HT3 RAs:
- **The FDA recommends a maximum of 16 mg for a single dose of intravenous ondansetron to prevent prolongation of the QT interval of the ECG. Dolasetron may increase the QT interval in a dose-dependent fashion.**
- **Granisetron extended-release injection is a unique formulation of granisetron using a polymer-based drug delivery system. This formulation is specifically intended for subcutaneous administration and is NOT interchangeable with the intravenous formulation. Granisetron extended-release injection has an extended half-life and should not be administered at less than 1-week intervals.**
- **Clinical pearl: After receiving palonosetron, granisetron transdermal patch, or extended-release injection, breakthrough 5-HT3 RAs play a limited role in the delayed infusion period and breakthrough antiemetic should focus on a different mechanism of action.**
- **Clinical pearl: Non-sedating; most common side effects are headache and constipation. Optimal effects seen with scheduled administration, not PRN use. Educate patients regarding constipation and its management.**

Corticosteroids:
- **Side effects associated with prolonged dexamethasone administration should be carefully considered.**
- **Dexamethasone may increase serum glucose; consider monitoring prior to therapy and as clinically indicated.**
- **Use with caution in patients with diabetes mellitus.**
- **Dexamethasone may cause dyspepsia; consider acid-blocking therapy with H2 antagonist or proton pump inhibitor as clinically indicated.**
- **Clinical pearl: For patients suffering from extended delayed CINV, consider extending the course of delayed dexamethasone as clinically appropriate. Consider AM dosing to minimize insomnia.**
- **Corticosteroid antiemetic premedication should be avoided for 3–5 days prior to and 90 days after CAR T-cell therapies.**

Olanzapine:
- **Monitor for dystonic reactions.[a]**
- **CNS depression; use olanzapine with caution or consider a lower dose in patients at risk for falls (eg, elderly, debilitated, frail) or at risk for orthostatic hypotension.**
- **Clinical pearl:**
  - **Consider a dose of 5 mg if the previously administered 10 mg dose caused excessive sedation. Data suggest that sedation is most notable on day 2 and improves over time.**
  - **Consider 2.5 mg of olanzapine if patients report excessive sedation with 5 mg dose.**
  - **Consider administration at bedtime due to sedation.**

[a] Use caution and monitor ECG in patients with other risk factors for QT prolongation.

Continued

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

PHARMACOLOGIC CONSIDERATIONS FOR ANTIEMETIC PRESCRIBING (In Order as the Drugs Appear in the Guideline)

Benzodiazepines:
- CNS depression; use caution in patients at risk for falls (eg, elderly, debilitated, frail) or in patients at risk for dependence.
- Clinical pearl: Consider for anticipatory CINV or when breakthrough CINV has an anxiety component.
- Use caution in patients receiving opioids due to increased risk of respiratory depression.

Phenothiazines:
- CNS depression; use caution in patients at risk for falls (eg, elderly, debilitated, frail).
- When administered parenterally, promethazine may cause severe tissue injury.
- Monitor for dystonic reactions.[b]
- Clinical pearl: Promethazine has more histamine blockade than prochlorperazine and is therefore more sedating.

Metoclopramide:
- Use caution in patients at risk for falls (eg, elderly, debilitated, frail).
- May increase the QT interval of the ECG.
- Monitor for dystonic reactions.[b]
- May cause tardive dyskinesia; the risk increases with increasing cumulative dose and duration of treatment.
- Clinical pearl: Metoclopramide increases gut motility and can be utilized to manage gastroparesis.

Haloperidol:
- CNS depression; use caution in patients at risk for falls (eg, elderly, debilitated, frail).
- May increase the QT interval of the ECG.
- Monitor for dystonic reactions.[b]
- Clinical pearl: Generally, lower doses of haloperidol (see AE-9 and AE-10) are required to produce an antiemetic effect than what is required for an antipsychotic effect.

Scopolamine:
- CNS depression; use caution in patients at risk for falls (eg, elderly, debilitated, frail).
- Clinical pearl: Consider using when positional changes, movement, or excessive secretions are triggering episodes of nausea/vomiting.

Cannabinoid:
- CNS depression; use caution in patients at risk for falls (eg, elderly, debilitated, frail).
- Clinical pearl: May stimulate appetite. To minimize adverse effects, consider starting with lower doses (especially in elderly or marijuana-naïve patients) and titrate to effect.

[b] Use diphenhydramine 25–50 mg PO/IV either every 4 or every 6 h for dystonic reactions. If allergic to diphenhydramine, use benztropine at 1–2 mg IV or IM x 1 dose, followed by oral dose of 1–2 mg daily or BID if needed. May consider using amantadine 100 mg BID-TID as treatment of drug-induced dystonic reactions for those patients intolerant of anticholinergic medications.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

PRINCIPLES FOR MANAGING BREAKTHROUGH EMESIS

- Breakthrough emesis presents a difficult situation, as correction of refractory ongoing nausea/vomiting is often challenging to reverse. It is generally far easier to prevent nausea/vomiting than it is to treat it.
- The general principle of breakthrough treatment is to give an additional agent from a different drug class. The choice of agent should be based on assessment of the current prevention strategies used. Some patients may require several agents utilizing differing mechanisms of action.
- One should strongly consider routine, around-the-clock administration rather than PRN dosing.
- The PO route is not likely to be feasible due to ongoing vomiting; therefore, rectal or IV therapy is often required.
- Multiple concurrent agents, perhaps in alternating schedules or by alternating routes, may be necessary. Dopamine antagonists (eg, phenothiazines, olanzapine, metoclopramide, haloperidol), corticosteroids, and agents such as lorazepam may be required.
- Ensure adequate hydration or fluid repletion, simultaneously checking and correcting any possible electrolyte abnormalities.
- Prior to administering the next cycle of chemotherapy the patient should be reassessed, with attention given to various possible non-chemotherapy–related reasons for breakthrough emesis with the current cycle:
  - Brain metastases
  - Electrolyte abnormalities
  - Tumor infiltration of the bowel or other gastrointestinal abnormality
  - Other comorbidities
- Prior to the next cycle of chemotherapy, reassess both the day 1 and post-chemotherapy antiemetic regimen, which did not protect the patient during the present cycle, and consider alternatives: (Suggestions are not in order of preference)
  - Add an NK1 RA if not previously included.
  - Consider changing from NK1 RA–containing regimens to olanzapine-containing regimen, or vice versa.
  - Consider combining an NK1 RA regimen with olanzapine; see High Emetic Risk Parenteral Chemotherapy - Acute And Delayed Emesis Prevention, option C (AE-4).
  - Possibly switch to a different NK1 RA with different pharmacokinetic/pharmacodynamic profile. Although no available head-to-head clinical trial data support this, anecdotal evidence suggests it may be helpful.
  - Add other concomitant antiemetics (eg, dopamine antagonists such as metoclopramide or haloperidol), if applicable.
  - Possibly adjust dose(s), either intensity or frequency, of the 5-HT3 RA. Based on the patient's experiences, the chemotherapy regimen in question may actually be more emetogenic than generally classified (eg, Hesketh method).
  - Possibly switch to a different 5-HT3 RA. Although not necessarily likely to be effective, anecdotal and limited investigational trial data suggest it may sometimes be efficacious. 5-HT3 RAs have different pharmacokinetics/pharmacodynamics and different routes of metabolism that may account for different efficacy in certain populations.
  - If the goal of chemotherapy is non-curative, consider other appropriate regimens, if any, that might be less emetogenic.
  - It may be beneficial to add an anxiolytic agent in combination with the antiemetic agents.
- Consider antacid therapy if patient has dyspepsia (H2 blocker or proton pump inhibitor).

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

Discussion

This discussion corresponds to the NCCN Guidelines for Antiemesis. Last updated on 04/23/2020.

Table of Contents

Overview

Vomiting (emesis) and nausea caused by anticancer agents and/or radiation therapy (RT) can significantly affect a patient's quality of life, leading to poor compliance with further anticancer agents and/or RT.[1,2] In addition, nausea and/or vomiting can result in dehydration, metabolic imbalances, degeneration of self-care and functional ability, nutrient depletion, anorexia, decline of the patient's performance status and mental status, wound dehiscence, esophageal tears, and withdrawal from potentially useful or curative anticancer treatment.[3-6] Anticancer agents include chemotherapy, targeted therapy, and immunotherapy, which will all be referred to as *anticancer agents* throughout this Discussion text.

The incidence and severity of nausea and/or vomiting in patients receiving anticancer agents and/or RT is affected by numerous factors, including: 1) the specific therapeutic agents used; 2) dosage of the agents; 3) schedule and route of administration of the agents; 4) target of the RT (eg, whole body, upper abdomen); and 5) individual patient variability (eg, younger age; female sex; prior anticancer agents; history of little or no alcohol use, morning sickness, motion sickness, anxiety).[7,8] More than 90% of patients receiving highly emetogenic chemotherapy (HEC) will have episodes of vomiting. However, if patients receive prophylactic (preventive) antiemetic regimens before treatment with HEC, then only about 30% of these patients will vomit.[7,9,10] Although vomiting can often be prevented or substantially decreased by using prophylactic antiemetic regimens, nausea is harder to control.[11-14]

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Antiemesis are intended to provide an overview of the treatment principles for preventing anticancer agent–induced or RT-induced nausea and/or vomiting, and recommendations for antiemetic prophylaxis according to the emetogenic potential of anticancer agents. The NCCN Guidelines® for Antiemesis are updated at least once a year by a multidisciplinary panel of experts; they were first published in 1997.[15] The *Summary of the Guidelines Updates* section in the algorithm briefly describes the new changes for 2020, which are described in greater detail in this Discussion; recent references have been added. Major updates for 2020 are summarized in this Discussion (see *Summary* in this Discussion). Additional supplementary material in the NCCN Guidelines for Antiemesis includes *Principles of Managing Multiday Emetogenic Chemotherapy Regimens, Pharmacologic Considerations for Antiemetic Prescribing,* and *Principles for Managing Breakthrough Emesis*. The NCCN Guidelines have also been modified for resource-restricted settings.[16] By definition, the NCCN Guidelines cannot incorporate all possible clinical variations and are not intended to replace good clinical judgment or individualization of treatments.

The NCCN Guidelines also provide specific category designations for all interventions in the guidelines, which are based on evidence from the biomedical literature and consensus among the panel members. Category 1 recommendations indicate uniform NCCN consensus (at least 85% of the panel vote) that the intervention is appropriate based on high-level evidence, such as randomized phase 3 trials. Category 2A recommendations indicate uniform NCCN consensus that the intervention is appropriate based on lower level evidence, such as phase 2 trials. It is important to note that all recommendations are category 2A in the NCCN Guidelines unless otherwise noted. By definition, the NCCN Guidelines cannot incorporate all possible clinical variations and are not intended to replace good clinical judgment or individualization of treatments. In contrast to other NCCN Guidelines in which most of the recommendations are category 2A, many of the recommendations for antiemetic regimens are category 1, reflecting the large number of randomized controlled trials (RCTs) that have focused on antiemetic management.

Literature Search Criteria and Guidelines Update Methodology

An electronic search of the PubMed database was performed to obtain key literature in antiemesis using the following search terms: chemotherapy-induced nausea vomiting, antiemetics chemotherapy. The PubMed database was chosen, because it is the most widely used resource for medical literature and indexes peer-reviewed biomedical literature. The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types: Clinical Trial, Phase 2; Clinical Trial, Phase 3; Clinical Trial, Phase 4; Guideline; Meta-Analysis; Randomized Controlled Trial; Systematic Reviews; and Validation Studies.

The data from key PubMed articles selected by the NCCN Panel for review during the NCCN Guidelines update meeting, as well as articles from additional sources deemed as relevant to these guidelines and discussed by the NCCN Panel, have been included in this version of the Discussion section (eg, e-publications ahead of print, meeting abstracts). If high-level evidence is lacking, recommendations are based on the panel's review of lower-level evidence and expert opinion. The complete details of the development and update of the NCCN Guidelines are available on the NCCN website (www.nccn.org).

Pathophysiology of Emesis

Vomiting results from stimulation of a multistep reflex pathway controlled by the brain.[1,7,17] Vomiting is triggered by afferent impulses to the vomiting center (located in the medulla) from the chemoreceptor trigger zone, pharynx and gastrointestinal (GI) tract (via vagal afferent fibers), and cerebral cortex. Vomiting occurs when efferent impulses are sent from the vomiting center to the salivation center, abdominal muscles, respiratory center, and cranial nerves.[18]

The chemoreceptor trigger zone, vomiting center, and GI tract have many neurotransmitter receptors. Activation of these receptors by chemotherapeutic agents or their metabolites may be responsible for anticancer agent–induced emesis. The principal neuroreceptors involved in the emetic response are the serotonin (5-hydroxytryptamine [5-HT3]) and dopamine receptors; 5-HT3 receptors are associated with acute emesis via a peripheral pathway.[1,19,20] Other neuroreceptors involved in emesis include acetylcholine, corticosteroid, histamine, cannabinoid, opioid, and neurokinin-1 (NK1) receptors, which are located in the vomiting and vestibular centers of the brain.[21] NK1 receptors are associated with delayed emesis via a central pathway.[1]

Antiemetics can block different neuronal pathways, exert their effects at different points during the course of emesis, or behave synergistically with other antiemetics to potentiate an antiemetic effect. When used at a certain concentration, each antiemetic agent predominantly blocks one receptor type. Olanzapine is the exception in that it acts on multiple receptors involved in the emetic pathway.[22] A final common pathway for emesis has yet to be identified. No single agent can be expected to provide complete protection from the various emetic phases of anticancer agents. Therefore, prophylactic antiemetic regimens for HEC and moderately emetogenic chemotherapy (MEC) include two to four antiemetics that block different receptors.

Nausea

With use of effective antiemetic regimens, patients receiving emetogenic anticancer agents often experience more nausea than vomiting.[11,12,23-26] Vomiting and nausea are related; however, they may occur via different mechanisms.[27,28] In general, younger patients are more likely to have nausea than older patients. Younger women receiving anticancer agents for breast cancer are more prone to nausea than other populations.[14] Delayed nausea is more common than acute nausea, is often more

severe, and tends to be resistant to treatment (see *Delayed Nausea* in this Discussion).[26]

Types of Nausea and/or Vomiting

Chemotherapy-Induced Nausea and/or Vomiting

Nausea and/or vomiting induced by anticancer agents has traditionally been referred to as chemotherapy-induced nausea and/or vomiting (CINV); it is commonly classified as acute, delayed, anticipatory, breakthrough, or refractory. *Acute-onset* nausea and/or vomiting usually occurs within a few minutes to several hours after administration of certain anticancer agents and commonly resolves within the first 24 hours. The intensity of acute-onset emesis generally peaks after 5 to 6 hours. Factors that influence acute emesis include type and dosage of the emetogenic agent, history of nausea and/or vomiting, environment in which anticancer agents are administered, and efficacy of the antiemetic regimen.[29] The occurrence of acute emesis is increased in younger (<50 years) women with a history of no or low ethanol use, motion sickness, or morning sickness.

Delayed-onset CINV develops in patients more than 24 hours after anticancer agent administration.[30,31] It occurs commonly with the administration of HEC, such as cisplatin, carboplatin, cyclophosphamide, and/or anthracyclines. For cisplatin, emesis reaches its maximal intensity 48 to 72 hours after administration and can last 6 to 7 days.

Anticipatory CINV occurs before patients receive their next treatment with anticancer agents. Because it is primarily considered a conditioned response, anticipatory emesis typically occurs after a previous negative experience with anticancer agents. The incidence of anticipatory CINV ranges from 18% to 57%, and nausea is more common than vomiting.[32,33] Younger patients may be more susceptible to anticipatory nausea and/or vomiting, because they generally receive more aggressive anticancer agents and, overall, have poorer emesis control than older patients.[34]

Breakthrough CINV refers to nausea and/or vomiting that occurs despite prophylactic antiemesis treatment and/or requires rescue with antiemetics.[35] *Refractory* CINV refers to nausea and/or vomiting that occurs during subsequent treatment cycles when antiemetic prophylaxis and/or rescue has not been effective in earlier cycles.[36]

Radiation-Induced Nausea and/or Vomiting

Patients receiving total body RT have the greatest likelihood of developing nausea and/or vomiting (>90% emesis); those receiving upper abdominal RT are at moderate risk of emesis (30%–90%).[35,37-39] The GI tract (specifically, the small intestine) contains rapidly dividing cells that are particularly sensitive to RT. In addition, the potential for nausea and/or vomiting increases with larger daily fractional doses of RT, larger total doses, and larger amounts of irradiated tissue. Total body irradiation, when given before bone marrow transplantation, commonly induces nausea and/or vomiting.[35,40,41]

Emetogenicity of Anticancer Agents

The frequency of anticancer agent–induced emesis depends primarily on the emetogenic potential of the specific chemotherapeutic agents used. Several classifications have been developed to define the emetogenicity of anticancer agents; however, none has been universally accepted.[18,42-45]

Hesketh and colleagues developed a classification of the acute emetogenicity of anticancer chemotherapeutic agents and developed an algorithm to define the emetogenicity of combination chemotherapeutic regimens.[9] The classification was updated by Grunberg et al; it divides chemotherapeutic agents into four levels according to the percentage of patients who experience acute emesis when they do not receive

antiemetic prophylaxis.[46] This classification is used in these NCCN Guidelines and is updated each year by the NCCN Panel with recently introduced drugs.

The NCCN Guidelines currently outline antiemetic treatment using four categories of emetogenic potential for parenteral agents, which correspond to the Hesketh/Grunberg classification as follows:

- High emetic risk—more than 90% of patients experience acute emesis;
- Moderate emetic risk—more than 30% to 90% of patients experience acute emesis;
- Low emetic risk—10% to 30% of patients experience acute emesis;
- Minimal emetic risk—fewer than 10% of patients experience acute emesis.

In addition, the NCCN Guidelines attempt to define antiemetic regimens for particular anticancer agents that cover the entire duration of time a patient is at risk for nausea and/or vomiting. Panel members were concerned that some patients may not receive adequate prophylaxis for delayed emesis; therefore, the NCCN Guidelines incorporate a dosing schedule that covers both acute and delayed emesis into single algorithms for HEC and MEC. The NCCN Panel has also categorized the emetogenic potential of oral anticancer agents.[46]

Clinicians should avoid overuse of antiemetics, especially in settings where the anticancer agents are of minimal or low emetic risk, to avoid exposing patients to adverse effects from antiemetics, to decrease possible drug-drug interactions, and to prevent unnecessary expense (see *Principles of Emesis Control for the Cancer Patient* in the NCCN Guidelines for Antiemesis).[37,47,48] Routine antiemetic premedication may not be required for continuous dosing of some low emetic risk parenteral agents or some moderate to high emetic risk oral agents; an individualized approach is appropriate in these settings. If clinicians use the emetogenic classification of anticancer agents in the NCCN Guidelines, this will decrease unnecessary prescribing of antiemetics.

For the 2020 update (Version 1), the NCCN Panel classified the emetogenic potential of 14 new anticancer agents based on clinical trial data (see the package inserts) and reclassified some agents based on clinical experience (see *Emetogenic Potential of Parenteral [and Oral] Anticancer Agents* in the NCCN Guidelines for Antiemesis). Enfortumab vedotin-ejfv and fam-trastuzumab deruxtecan-nxki are parenteral anticancer agents that were classified as moderate emetic risk. Mogamulizumab, moxetumomab, polatuzumab vedotin, and tagraxofusp are parenteral anticancer agents that were classified as low emetic risk; arsenic trioxide was reclassified as low emetic risk.[49] Cemiplimab and trastuzumab/hyaluronidase are parenteral anticancer agents that were classified as minimal emetic risk. Avapritinib and selinexor are oral anticancer agents that were classified as moderate to high emetic risk; binimetinib and encorafenib were reclassified as moderate to high emetic risk.[50] Alpelisib, entrectinib, erdafitinib, and zanubrutinib are oral anticancer agents that were classified as minimal to low emetic risk; trifluridine/tipiracil was reclassified as minimal to low emetic risk.[51] The panel feels that the emetic risk for biosimilars is generally expected to be the same as for the parent compound unless otherwise noted.[52]

Types of Antiemetic Therapies

In general, to provide maximal protection against anticancer agent–induced emesis, antiemetic therapy should be initiated before treatment with anticancer agents. The antiemetic therapy should also be continued for the same length of time as the duration of the anticancer agents being used. However, daily use of certain antiemetics, such as dexamethasone, may not be recommended for some anticancer agents that are taken long-term on a regular basis, such as the oral anticancer agents of moderate/high emetic risk (see the NCCN Guidelines for Antiemesis).

Antiemetics can be administered by the oral, sublingual, rectal, intravenous, intramuscular, subcutaneous, or transdermal route. Oral and parenteral 5-HT3 antagonists have equivalent efficacy when used at the appropriate doses.[10,41] However, subcutaneous granisetron extended-release injection and intravenous granisetron are not interchangeable; the subcutaneous formulation should not be given intravenously and vice versa. Aprepitant injectable emulsion and intravenous fosaprepitant are also not interchangeable. The dosing is different for all of these formulations. For patients at risk for CINV or unable to swallow or digest tablets because of emesis, non-oral antiemetics are recommended.

Although studies may show antiemetics to be equally effective on a population basis, individual patients may respond differently. Therefore, some antiemetic options may be based on a patient's individual experience. Patients may be at risk for drug-drug interactions if they are receiving anticancer agents along with antiemetic regimens; clinicians should balance benefit and risk for each patient. For the 2020 update, the NCCN Panel added caveats about drug-drug interactions after extensive discussions (see *Principles of Emesis Control for the Cancer Patient* in the NCCN Guidelines for Antiemesis). Many drug-drug interactions between antiemetics and anticancer agents occur with chronic dosing and are often not clinically relevant with short-term use of prophylactic antiemetic regimens, as shown by the lack of clinically significant drug-drug interactions in randomized trials of anticancer agents along with antiemetic regimens.[53] The NCCN Panel also revised previous statements about the potential risk for drug-drug interactions for the 2020 update. The panel deleted previous precautions about using immune checkpoint inhibitor monotherapy with corticosteroid antiemetic regimens. However, corticosteroid antiemetics should be avoided for 3 to 5 days before and 90 days after chimeric antigen receptor (CAR) T-cell therapies. Replacing dexamethasone with olanzapine is an option for patients who cannot tolerate or take steroids. The panel also deleted recommendations for electrocardiogram (ECG) monitoring in patients taking antiemetics such as olanzapine, benzodiazepines, or haloperidol.

Serotonin (5-HT3) Antagonists

Ondansetron, Granisetron, and Dolasetron

All of the 5-HT3 antagonists—dolasetron mesylate, granisetron, ondansetron, and palonosetron—have been shown to be effective in controlling the acute nausea and/or vomiting associated with anticancer agents.[54-70] Ondansetron, granisetron, and dolasetron mesylate are first-generation 5-HT3 antagonists. Many clinical trials have compared ondansetron, granisetron, dolasetron mesylate, and palonosetron. These trials have used various doses, routes, and schedules of administration.[71-88] A meta-analysis found no difference in efficacy between the first-generation 5-HT3 antagonists.[89] Another meta-analysis of studies comparing ondansetron with granisetron has also confirmed the similar efficacy of these first-generation 5-HT3 antagonists in controlling acute and delayed nausea and vomiting, with similar safety profiles between these agents.[90]

A meta-analysis of RCTs comparing palonosetron with the first-generation 5-HT3 antagonists reported that palonosetron was significantly more effective in preventing acute and delayed nausea and vomiting for both HEC and MEC; most patients receiving MEC actually received anthracycline and cyclophosphamide (AC regimens).[91] However, AC regimens are now classified as HEC, although they were previously classified as MEC.[37,92] Based on this meta-analysis and clinical practice, some NCCN Panel Members feel that palonosetron should be a preferred 5-HT3 antagonist for both HEC and MEC. However, the majority of the NCCN Panel previously decided that palonosetron is only preferred for MEC if the regimen does not contain an NK1 receptor antagonist (RA) (see *Palonosetron* in this Discussion).[72] Similar to palonosetron, the panel

also recommends subcutaneous granisetron extended-release injection as a preferred 5-HT3 antagonist option when used with dexamethasone in antiemetic regimens that do not contain an NK1 RA (see *Principles of Managing Multiday Emetogenic Chemotherapy Regimens* in the NCCN Guidelines for Antiemesis).[93]

Ondansetron, granisetron, and dolasetron are effective in preventing acute emesis but appear to be less effective for delayed emesis. A meta-analysis of RCTs found that adding a 5-HT3 antagonist to dexamethasone did not improve the antiemetic effect of dexamethasone for preventing delayed emesis.[94] Another study found that 5-HT3 antagonists (except palonosetron, which was not studied) were not more effective than prochlorperazine in preventing delayed emesis.[26] A single dose of intravenous palonosetron appears to be effective for preventing both delayed and acute emesis.

The NCCN Guidelines recommend intravenous palonosetron as a preferred 5-HT3 antagonist for MEC when used with dexamethasone but without an NK1 RA (see *Principles of Managing Multiday Emetogenic Chemotherapy Regimens* in the NCCN Guidelines for Antiemesis).[72] Several studies[95-98] have evaluated the efficacy of a 3-drug combination regimen with palonosetron, dexamethasone, and NK1 RAs as prophylaxis in patients receiving MEC (see *Neurokinin-1-Receptor Antagonists* in this Discussion). However, these studies do not provide evidence that a single dose of palonosetron is better than a single dose of a first-generation 5-HT3 antagonist when using an NK1-antagonist–containing regimen for MEC.

A phase 3 trial assessed subcutaneous granisetron extended-release injection versus intravenous palonosetron in a 2-drug regimen with dexamethasone for patients receiving HEC or MEC.[93] Two doses of subcutaneous granisetron extended-release injection were assessed: 5 mg and 10 mg. The data show that subcutaneous granisetron extended-release injection is not inferior to intravenous palonosetron for preventing acute and delayed CINV after either HEC or MEC. For patients receiving HEC, acute complete responses (CRs) for the 5- or 10-mg granisetron doses were 77.7% (−12.1, 6.1) and 81.3% (−8.2, 9.3), respectively, compared with 80.7% for those receiving a 0.25-mg dose of intravenous palonosetron. For patients receiving MEC, acute CRs for 5 mg or 10 mg of subcutaneous granisetron were 74.8% (−9.8, 9.3) and 76.9% (−7.5, 11.4), respectively, compared with 75.0% for palonosetron. The FDA approved the use of a 10-mg dose of subcutaneous granisetron extended-release injection when used in antiemetic regimens for MEC or AC combination anticancer agent regimens. Based on this trial and the FDA approval, the NCCN Panel now recommends intravenous palonosetron or subcutaneous granisetron extended-release injection as preferred 5-HT3 antagonists for MEC when used with dexamethasone in 2-drug antiemetic regimens that do not contain an NK1 RA. The panel does not recommend these 2-drug antiemetic regimens for HEC. The panel recommends for HEC either a 4-drug preferred regimen (which includes olanzapine and an NK1 RA) or 3-drug antiemetic regimens, which include an NK1 RA or olanzapine.

MAGIC, a phase 3 randomized trial, assessed a single dose of subcutaneous granisetron extended-release injection compared with a single dose of intravenous ondansetron in a 3-drug regimen with dexamethasone and fosaprepitant for patients receiving HEC.[99,100] The data show that the regimen containing granisetron extended-release injection improved the CR rate (no emesis or rescue medication) for delayed-phase CINV (24–120 hours) compared with the ondansetron regimen (P = .014). This was the first published trial that compared a single dose of two different 5-HT3 antagonists when used in combination with dexamethasone and an NK1 RA. As a result, granisetron extended-release injection was the first FDA-approved 5-HT3 antagonist indicated for the prevention of delayed CINV associated with AC

anticancer agents. When administered subcutaneously, granisetron extended-release injection is effective for 5 or more days.

The NCCN Panel recommends a 10-mg dose of subcutaneous granisetron extended-release injection on day 1 only for patients receiving either HEC or MEC when used in the antiemetic regimens based on the MAGIC trial, the trial comparing dexamethasone with either palonosetron or subcutaneous granisetron, and the FDA approval.[93,99,100] It is important to note that granisetron extended-release injection is a unique formulation of granisetron using a polymer-based drug delivery system. This formulation is specifically intended for subcutaneous administration and is NOT interchangeable with the intravenous formulation; the subcutaneous formulation should not be injected and vice versa. Subcutaneous granisetron extended-release injection has an extended half-life and should not be administered at less than 1-week intervals.

Ondansetron and granisetron can be delivered orally or intravenously; granisetron extended-release injection is administered subcutaneously. Note that intravenous dolasetron or 32 mg of ondansetron is no longer recommended for the prevention of nausea and/or vomiting, because they have been associated with an increased risk for cardiac arrhythmias (see *Cardiac Side Effects* in this Discussion).[101-104] Oral administration of ondansetron poses less of a risk for cardiac arrhythmias than intravenous administration.[103] Oral dolasetron is still recommended.

A phase 3 randomized trial compared the granisetron transdermal patch to oral granisetron in patients receiving either HEC or MEC. The patch contains 3.1 mg of granisetron/24 hours and is applied approximately 24 to 48 hours before the first dose of anticancer agents; the maximum duration of the patch is 7 days. The patch proved non-inferior to repeat dosing of the oral antiemetic granisetron over 3 to 5 days.[13,24,105] A phase 4 trial assessed an antiemetic regimen containing the transdermal granisetron patch versus a palonosetron regimen for patients receiving MEC; transdermal granisetron was not inferior to palonosetron in preventing nausea and vomiting in the acute stage.[106] The NCCN Panel recommends the granisetron transdermal patch as a 5-HT3 option when used as part of recommended antiemetic regimens for patients receiving either HEC or MEC based on clinical trial data and the FDA approval.[24,105,106] No further 5-HT3 therapy is required on days 2 and 3 if a granisetron transdermal patch is applied on day 1 or if palonosetron or granisetron extended-release injection is given on day 1.

The addition of dexamethasone improves the efficacy of antiemetic regimens containing 5-HT3 antagonists (see *Dexamethasone* in this Discussion). However, dexamethasone is associated with side effects, such as insomnia. When dexamethasone is used with palonosetron for MEC, a randomized trial suggests that the dose of dexamethasone can be decreased to 8 mg on day 1 and also eliminated on days 2 to 3.[107]

Cardiac Side Effects

Ondansetron, granisetron, and dolasetron have been associated with an increased risk for developing abnormal electrical activity of the heart that is detectable on ECG, including prolongation of electrocardiographic intervals, such as PR or QT intervals.[103,104,108-115] Although the ECG changes can be reversible and asymptomatic, abnormal activity can also result in potentially fatal cardiac arrhythmias (including torsade de pointes) in some cases.[103] Patients who may be particularly at risk for developing torsade de pointes include those with congenital long QT syndrome or other underlying cardiac diseases, congestive heart failure, bradycardia, those with electrolyte abnormalities (eg, hypokalemia, hypomagnesemia), and those taking other medications that can lead to QT prolongation.[104,112,116] A single intravenous dose of 32 mg of ondansetron is no longer recommended based on FDA review of clinical data suggesting prolongation of the QT interval of the ECG at this dose.[101-103] The FDA recommends a maximum single intravenous dose of 16 mg of

ondansetron given once on the first day; the dose recommendations for oral administration of ondansetron are 16 to 24 mg given once on the first day.[102] Intravenous dolasetron is no longer recommended for the prevention of nausea and vomiting, because it has been associated with an increased risk for cardiac arrhythmias.[103,104]

Palonosetron

Palonosetron is a 5-HT3 antagonist with an approximately 100-fold higher binding affinity for the 5-HT3 receptor compared to ondansetron, granisetron, and dolasetron. Palonosetron has a half-life of approximately 40 hours, which is significantly longer than other commercially available 5-HT3 antagonists.[56] Data suggest that palonosetron is associated with prolonged inhibition of the 5-HT3 receptor and thus differs from ondansetron, granisetron, and dolasetron.[117,118] By suppressing cross talk between 5-HT3 and NK1 signaling pathways, palonosetron may indirectly inhibit substance P.

Several randomized phase 3 trials have assessed the efficacy of palonosetron compared with other 5-HT3 antagonists in preventing emesis associated with both MEC and HEC regimens, particularly for delayed emesis.[71-74] In these studies, the primary efficacy endpoint was CR, defined as having no emesis and no rescue treatments. In a study in patients receiving MEC (N = 563 evaluable), a single dose of palonosetron (0.25 mg intravenous) was found to be superior to a single dose of ondansetron (32 mg intravenous) in preventing both acute (CR rate, 81% vs. 69%; $P < .01$) and delayed emesis (CR rate, 74% vs. 55%; $P < .01$); no concomitant corticosteroids were given in this study.[74] The safety and side-effect profiles of palonosetron were indistinguishable from the control 5-HT3 antagonists (ondansetron and dolasetron). Note that the FDA now recommends a maximum of 16 mg for a single dose of intravenous ondansetron.[103]

A phase 3 randomized trial compared palonosetron with ondansetron in patients receiving HEC (N = 667), and most patients (67%) received dexamethasone on day 1 of antiemetic therapy; NK1 RAs were not used in this trial.[71] Among this subgroup of patients who received concomitant dexamethasone (n = 447), palonosetron (0.25 mg intravenous) was similar to ondansetron (32 mg intravenous) in preventing acute emesis (CR rate, 65% vs. 56%); however, palonosetron was significantly more effective in preventing delayed emesis (CR rate, 41% vs. 25%; $P = .021$).

Another phase 3 randomized trial in patients treated with HEC (N = 1114 evaluable) compared a single dose of palonosetron (at a higher dose of 0.75 mg intravenous) with a single dose of granisetron (40 mcg/kg intravenous), both in combination with dexamethasone; NK1 RAs were not used in this trial. Palonosetron showed similar activity to granisetron in preventing acute emesis (CR rate, 75% vs. 73%) and superior activity in preventing delayed emesis (CR rate, 57% vs. 44.5%; $P < .0001$).[72] A meta-analysis of 24 RCTs assessed whether palonosetron was more effacious than the other 5-HT3 antagonists. Although palonosetron seems to be more efficacious and safe than other 5-HT3 RAs and was statistically superior in 10 of 19 endpoints, overall the authors suggest that palonosetron should generally not be the preferred 5-HT3 antagonist.[119] The NCCN Panel does not recommend palonosetron as the preferred 5-HT3 antagonist in regimens for HEC, because an NK1 RA was not used in these studies and it is unknown if a single dose of palonosetron would be superior to a single dose of granisetron in the presence of an NK1 RA.[71,72,74,119,120]

As previously mentioned, the NCCN Panel recommends either palonosetron or subcutaneous granisetron extended-release injection as preferred 5-HT3 antagonists for MEC when used with dexamethasone in 2-drug antiemetic regimens that do not contain an NK1 RA (see *Ondansetron, Granisetron, and Dolasetron* in this Discussion and

Principles of Managing Multiday Emetogenic Chemotherapy Regimens in the NCCN Guidelines for Antiemesis).[93] Palonosetron (0.25 mg intravenous) is FDA approved as a single dose on day 1 for the prevention of acute and delayed nausea and vomiting associated with MEC and for the prevention of acute nausea and vomiting associated with HEC. No further 5-HT3 therapy is required for MEC on days 2 and 3 if palonosetron or granisetron extended-release injection is given on day 1 or if granisetron transdermal patch is applied on day 1.

Intravenous palonosetron is superior to other first-generation 5-HT3 antagonists in preventing delayed nausea.[25,71-74] Repeat dosing of palonosetron on days 2 or 3 after anticancer agents is likely to be safe. However, in the setting of multiday anticancer agents, limited data are available to recommend multiday dosing with palonosetron (see *Principles of Managing Multiday Emetogenic Chemotherapy Regimens* in the NCCN Guidelines for Antiemesis).[121]

Neurokinin-1-Receptor Antagonists

For patients receiving HEC and MEC, the NCCN Panel recommends several options for prophylactic antiemetic regimens based on clinical trial data and FDA approvals, including: 1) NK1 RA-containing regimens, which are discussed in this section; and 2) olanzapine-containing regimens. NK1 RA regimens include oral aprepitant, IV fosaprepitant, oral rolapitant, oral netupitant, or IV fosnetupitant. It is important to note that oral netupitant (or IV fosnetupitant) is only available in combination with palonosetron (NEPA); netupitant is not available as a single agent.

A prophylactic 2-drug regimen of one of the 5-HT3 antagonists plus dexamethasone is recommended for MEC but not HEC. However, a prophylactic 3-drug antiemetic regimen that includes either an NK1 RA or olanzapine is recommended for select patients receiving MEC who have additional risk factors or previous treatment failure with the 2-drug regimen. These additional risk factors include younger age; female sex; anxiety and/or high pretreatment expectation of nausea and/or vomiting; and history of CINV, motion sickness, morning sickness during pregnancy, and little or no alcohol use.[122] This list of risk factors was updated for the 2020 guidelines. Patients receiving anticancer agents that are classified as moderate emetic risk but are at the higher end of the risk spectrum (eg, carboplatin, carmustine, cyclophosphamide, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, ifosfamide, irinotecan, methotrexate, oxaliplatin, trabectedin) are at greater risk for emesis and may also need a 3-drug prophylactic antiemetic regimen.

Aprepitant

Aprepitant selectively blocks the binding of substance P at the NK1 receptor in the central nervous system. Thus, aprepitant provides a different and complementary mechanism of action compared with other commercially available antiemetics. Aprepitant has been shown to augment the antiemetic activity of the 5-HT3 antagonists and the corticosteroid dexamethasone to prevent both acute and delayed cisplatin-induced emesis.[123-125] Most of the clinical trial data described in this Discussion are based on studies with oral aprepitant. Aprepitant injectable emulsion is a formulation of aprepitant that is approved by the FDA for HEC and MEC when used in combination with other antiemetic regimens.[126]

Oral Aprepitant

A randomized phase 3 trial compared ondansetron 32 mg intravenous and oral dexamethasone with or without the addition of oral aprepitant in patients receiving emetogenic chemotherapy with high-dose cisplatin (N = 521 evaluable). The addition of oral aprepitant was significantly more effective than the 2-drug regimen in controlling both acute (CR rate, 89% vs. 78%; $P < .001$) and delayed emesis (CR rate, 75% vs. 56%; $P < .001$).[124] Another similarly designed randomized phase 3 study (N = 523

evaluable) also showed a significant benefit of adding oral aprepitant to ondansetron and dexamethasone compared with the 2-drug regimen alone for controlling both acute (CR rate, 83% vs. 68%; $P < .001$) and delayed emesis (CR rate, 68% vs. 47%; $P < .001$).[125] A pooled analysis of data combined from these two phase 3 trials found that the oral aprepitant regimen was particularly beneficial in improving CR rates for patients receiving concomitant emetogenic therapy with doxorubicin and cyclophosphamide (AC regimen) or cyclophosphamide, along with high-dose cisplatin therapy.[123]

A large meta-analysis (of 17 RCTs) evaluated outcomes with typical antiemetic therapy with or without oral aprepitant in patients receiving MEC or HEC. The addition of oral aprepitant was associated with significantly improved CR (no emetic episodes and no rescue medication) rate compared with control antiemetic therapy (72% vs. 54%; $P < .001$) during the overall timeframe from 0 to 120 hours after starting anticancer agents.[127] The significant increase in CR rate associated with oral aprepitant was observed for both the acute and delayed periods. A smaller meta-analysis (of seven RCTs) of patients receiving HEC found that oral aprepitant used alone or with control antiemetic therapy did not significantly increase protection from acute emesis or nausea; however, for delayed emesis and nausea, oral aprepitant was associated with significantly increased protection compared with control.[128] Based on data from three trials that reported on infectious complications, both oral aprepitant regimens and other antiemetic regimens were associated with a low rate of severe infections (6% vs. 2%; $P < .001$); the risk of febrile neutropenia or other hematologic toxicities was not increased.[127] A randomized phase 3 trial (N = 866) showed that an oral aprepitant regimen was more effective than a control antiemetic regimen in preventing vomiting in patients receiving HEC during 120 hours after initiation of anticancer agents (CR rate, 51% vs. 43%; $P = .015$); no delayed dexamethasone was used in this trial. However, approximately 40% of patients receiving either regimen still experienced significant nausea.[129] The oral aprepitant regimen included ondansetron and dexamethasone; the control antiemetic regimen included ondansetron and dexamethasone.

A 3-drug antiemetic regimen with palonosetron, dexamethasone, and oral aprepitant has also been investigated in patients undergoing treatment with HEC. A phase 2 study in patients receiving HEC with cisplatin-containing regimens (N = 222) showed that the 3-drug combination of palonosetron (0.25 mg intravenous day 1), oral aprepitant (125 mg day 1; 80 mg days 2, 3), and dexamethasone (20 mg intravenous day 1; 4 mg oral days 2, 3) resulted in a CR rate (no emetic episodes and no rescue medication) of 70% during the overall study period (0–120 hours).[97] In addition, 93% of patients had no emesis and 60% had no nausea during the study period. Constipation was the most commonly reported adverse event (39%).[97] A phase 2 study evaluated a higher dose of palonosetron (0.75 mg intravenous day 1) with oral aprepitant (125 mg day 1; 80 mg days 2, 3) and dexamethasone (10 mg oral day 1; 8 mg oral days 2–4) in patients with lung cancer undergoing HEC (N = 63); the CR rate was 81% during the overall study period (0–120 hours).[98] The CR rates during the acute and delayed phases were 97% and 81%, respectively. In addition, 54% of patients had no nausea during the overall study period. Grade 1 or 2 constipation was the most commonly reported adverse event.[98]

A phase 3 trial added oral aprepitant to a control antiemetic regimen of oral granisetron and oral dexamethasone in patients receiving MEC. The addition of oral aprepitant improved control of nausea, vomiting, and quality of life compared with granisetron and dexamethasone.[130] A phase 2 study (N = 58) found that combining palonosetron (0.25 mg intravenous day 1), oral aprepitant (125 mg day 1; 80 mg days 2, 3), and dexamethasone (12 mg day 1; 8 mg days 2, 3) was effective in preventing

both acute and delayed emesis and nausea when using various chemotherapeutic regimens (moderate to moderately highly emetogenic); 78% of patients had a CR (no emetic episodes and no rescue medication) during the overall timeframe, from 0 to 120 hours after initiation of emetogenic therapy.[95] A phase 2 study in patients with breast cancer (N = 41) receiving MEC also found that a single-day regimen of palonosetron (0.25 mg intravenous), oral aprepitant (285 mg oral), and dexamethasone (20 mg) was effective; 76% and 66% of patients had a CR during the acute and delayed phases, respectively.[96]

A randomized double-blind phase 3 trial compared the effectiveness of combining ondansetron (8 mg oral twice daily [BID] day 1), oral aprepitant (125 mg day 1; 80 mg days 2, 3), and dexamethasone (12 mg day 1) versus control antiemetic therapy with ondansetron (8 mg oral BID days 1–3) and dexamethasone (20 mg day 1) in patients receiving MEC (N = 585).[131] Dexamethasone was only given on day 1 for both treatment groups. A significantly higher proportion of patients in the 3-drug regimen with oral aprepitant had no vomiting compared with the control antiemetic regimen (76% vs. 62%; $P < .001$) during the overall timeframe from 0 to 120 hours after starting anticancer agents. In addition, the CR (no emetic episodes, no rescue medications) rate was significantly increased in the oral aprepitant group (69% vs. 56%; $P < .001$) during the overall time period. The significant improvement in antiemetic activity (with regard to no emesis as well as CR rate) in the oral aprepitant group was observed for both the acute and delayed phases. The 3-drug regimen was well tolerated, and the incidence of adverse events was similar between treatment groups.[131] Oral aprepitant is FDA approved for the prevention of nausea and vomiting in patients receiving HEC (eg, cisplatin-containing) and MEC. The oral doses of aprepitant are 125 mg on day 1 (before anticancer agents) and then 80 mg on days 2 and 3 (after anticancer agents).[132]

The NCCN Panel recommends prophylactic oral aprepitant in combination with dexamethasone, a 5-HT3 RA, and with or without olanzapine (category 1) for acute and delayed emesis prevention for HEC and MEC based on clinical trial data and on FDA approvals.[123,124,133]

Fosaprepitant

Fosaprepitant dimeglumine is an intravenous version of aprepitant, which can be given on day 1 only; it is also FDA approved. A single dose of 150 mg intravenous fosaprepitant was shown to be non-inferior to the control antiemetic regimen with 3-day oral aprepitant in a randomized study.[134] As previously mentioned, intravenous fosaprepitant is NOT interchangeable with aprepitant injectable emulsion. Intravenous fosaprepitant is given 30 minutes before anticancer agents on day 1 only, per the package insert. If a higher dose of fosaprepitant is used (150 mg intravenous) on day 1, then it is not necessary to give oral aprepitant on days 2 to 3.[135,136] Note that the dexamethasone dosing is slightly different on days 3 and 4 (8 mg PO/IV BID) when using the higher dose of fosaprepitant (150 mg intravenous) per the package insert. There are no studies showing efficacy or safety of chronic dosing with oral aprepitant. It is possible that the drug-drug interaction profile may change with chronic dosing.

The NCCN Panel recommends prophylactic fosaprepitant in combination with dexamethasone, a 5-HT3 RA, and with or without olanzapine (category 1) for acute and delayed emesis prevention for HEC and MEC based on clinical trial data and on FDA approvals.[134]

Aprepitant Injectable Emulsion

Intravenous fosaprepitant contains polysorbate 80 and other surfactants that may cause infusion-site reactions including pain, erythema, and swelling.[126,137,138] Aprepitant injectable emulsion is a formulation of aprepitant that does not contain polysorbate 80 and other surfactants. A phase 1 bioequivalence study (n = 100) compared intravenous

fosaprepitant with aprepitant injectable emulsion.[126] Patients receiving aprepitant injectable emulsion had fewer treatment-emergent adverse effects compared with those receiving intravenous fosaprepitant (1% vs. 20%); all these adverse events resolved. Three patients receiving intravenous fosaprepitant had dyspnea. None of the patients had severe treatment-emergent adverse effects, serious adverse events, or resultant death. Aprepitant injectable emulsion was bioequivalent to intravenous fosaprepitant (bioequivalence bounds, 80%–125%).

The NCCN Panel recommends prophylactic aprepitant injectable emulsion in combination with dexamethasone, a 5-HT3 RA, and with or without olanzapine (category 1) for acute and delayed emesis prevention for HEC and MEC based on clinical trial data and on FDA approvals.[126] As previously mentioned, aprepitant injectable emulsion is not interchangeable with intravenous fosaprepitant.

Drug Interactions

Aprepitant is simultaneously a substrate, moderate inducer, and moderate inhibitor of cytochrome P450 enzyme 3A4 (CYP3A4); aprepitant also induces CYP2C9.[139] Thus, aprepitant can alter the metabolism of certain drugs and change their plasma concentrations (ie, areas under the curve [AUCs]). However, these interactions are more significant with orally administered forms of these drugs than with intravenous forms because of first-pass metabolism. Patients should not take oral aprepitant or aprepitant injectable emulsion with pimozide or astemizole; these combinations are contraindicated because they may cause serious or life-threatening reactions (see the aprepitant package inserts). Chemotherapeutic agents known to be metabolized by CYP3A4 include docetaxel, paclitaxel, etoposide, irinotecan, ifosfamide, imatinib, vinorelbine, vinblastine, and vincristine. In clinical trials, oral aprepitant was used concurrently with etoposide, vinorelbine, or paclitaxel; although anticancer agent doses were not adjusted for potential drug interactions in phase 3 trials, no observed adverse effect or decreased efficacy was observed; caution is urged when using any chemotherapeutic agent that is metabolized by CYP3A4. A systematic review also describes potential drug-drug interactions with aprepitant and fosaprepitant.[140] However, short-term use of antiemetics may not result in clinically relevant drug interactions.[53]

Aprepitant has been shown to interact with several non-chemotherapeutic drugs, including warfarin, dexamethasone, methylprednisolone, and oral contraceptives. Induction of warfarin metabolism by aprepitant may lead to clinically significant reductions in INR (international normalized ratio) values, particularly for patients on therapeutic (as compared to prophylactic) warfarin regimens. These changes, although brief in duration, may require increased patient monitoring. Aprepitant decreases the AUC for patients taking oral contraceptives; thus, other methods of birth control should be used during treatment with aprepitant and for 1 month after the last dose of aprepitant. Additionally, certain drugs can affect the AUCs of aprepitant. Concomitant administration with CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin) may lead to increased aprepitant AUCs, whereas concomitant administration with CYP3A4 inducers (eg, carbamazepine, rifampin, phenytoin) may lead to decreased levels of aprepitant.

Netupitant (or Fosnetupitant) and Palonosetron (NEPA)

Netupitant is a highly selective NK1 RA that targets serotonin and substance P–mediated pathways involved in CINV. Oral netupitant is combined with oral palonosetron (NEPA) in a single tablet, and netupitant is not available as a single agent; oral NEPA is approved by the FDA for the prevention of nausea and vomiting in patients receiving HEC and MEC based on several randomized trials.[141-144] Intravenous fosnetupitant is combined with intravenous palonosetron (IV NEPA), and fosnetupitant is also not available as a single agent; IV NEPA is approved by the FDA for

the prevention of nausea and vomiting in patients receiving HEC and other types of anticancer agents.

A randomized trial in patients receiving HEC assessed dexamethasone plus 3 dose levels of prophylactic oral NEPA compared with oral palonosetron plus dexamethasone.[141] The oral NEPA fixed-dose combination of 300 mg of netupitant decreased nausea and vomiting in the acute, delayed, and overall phases versus palonosetron alone. The CR for the NEPA300 arm was 89.6% versus 76.5% for the palonosetron arm ($P < .050$). A randomized phase 3 trial in patients receiving AC regimens assessed oral NEPA plus dexamethasone compared with palonosetron plus dexamethasone.[143] More patients in the oral NEPA arm had CR during the delayed phase compared with the control arm (76.9% vs. 69.5%; $P = .001$). In addition, patients in the oral NEPA arm also had more CRs in the overall phases (0–120 h) (74.3% vs. 66.6%; $P = .001$) and acute phases (0–24 h) (88.4% vs. 85.0%; $P = .047$).

A phase 3 randomized trial assessed a single dose of oral NEPA compared with a 3-day aprepitant/granisetron regimen in patients (n = 828) receiving HEC; all patients received oral dexamethasone on days 1 through 4.[145] The oral NEPA regimen was non-inferior to the aprepitant regimen (overall CR: oral NEPA, 73.8% vs. aprepitant/granisetron, 72.4%; 95% CI, -4.5%–7.5%). Similar rates were observed for both groups for no emesis (oral NEPA, 75.0% vs. aprepitant/granisetron, 74.0%; 95% CI, -4.8%–6.9%) and no significant nausea (oral NEPA, 75.7% vs. aprepitant/granisetron, 70.4%; 95% CI, -0.6%–11.4%).

The NCCN Panel recommends prophylactic oral or IV NEPA in combination with dexamethasone and with or without olanzapine (category 1) for acute and delayed emesis prevention for HEC and MEC based on randomized trials, FDA approvals, and clinical experience.[141,143,145,146] Currently, IV NEPA is only FDA approved for HEC. However, the NCCN Panel recommends IV NEPA regimens for MEC based on clinical experience.

Similar to the other NK1 RAs (ie, oral aprepitant, IV fosaprepitant, oral rolapitant), netupitant and fosnetupitant improve control for delayed emesis compared with traditional antiemetic regimens. Netupitant and fosnetupitant inhibit CYP3A4; therefore, caution should be used with drugs that are metabolized by CYP3A4 to avoid drug interactions (see prescribing information). Concomitant use with certain agents that are strong inducers (eg, rifampin) of CYP3A4 is contraindicated. However, short-term use of antiemetics may not result in clinically relevant drug interactions.

Rolapitant

Oral rolapitant is another NK1 RA that is approved by the FDA for the prevention of nausea and vomiting in patients receiving HEC and other types of anticancer agents based on several phase 3 randomized trials.[147,148] In a phase 3 randomized trial assessing a prophylactic oral rolapitant-containing regimen for HEC, patients received 180 mg of oral rolapitant on day 1 only; all patients received granisetron (10 mcg/kg intravenously) and dexamethasone (20 mg orally) on day 1, and dexamethasone (8 mg orally) BID on days 2 to 4.[148] More patients receiving the oral rolapitant-containing regimen had CRs for prevention of delayed emesis compared with those receiving granisetron/dexamethasone alone (pooled studies: 382 [71%] vs. 322 [60%]; odds ratio [OR], 1.6; 95% CI, 1.3–2.1; $P = .0001$). For patients receiving HEC, the NCCN Panel recommends several prophylactic antiemetic regimens (category 1); a 5-HT3 antagonist, dexamethasone, and oral rolapitant regimen with or without olanzapine is recommended for acute and delayed emesis prevention based on the FDA approval and the phase 3 randomized trial.[148]

A randomized phase 3 trial assessed a prophylactic oral rolapitant-containing regimen for anticancer regimens previously considered to be MEC, which are now categorized as HEC by the NCCN Panel (ie, AC regimens and regimens containing carboplatin with an AUC ≥4). With the revised definition of HEC regimens, this trial actually contained mostly HEC and only some MEC regimens (18% and 14% of patients had non-AC regimens and non-carboplatin regimens).[92,147] Most patients also received granisetron (2 mg orally) and dexamethasone (20 mg orally) on day 1 followed by granisetron (2 mg orally) on days 2 to 3.[147] Significantly more patients receiving the oral rolapitant-containing regimen had CRs in the delayed phase than did those receiving granisetron/dexamethasone alone (475 [71%] vs. 410 [62%]; OR, 1.6; 95% CI, 1.2–2.0; *P* = .0002). For patients receiving MEC, the NCCN Panel recommends several prophylactic antiemetic regimens (category 1); a 5-HT3 antagonist/dexamethasone (category 1) with (or without) oral rolapitant is recommended for acute and delayed emesis prevention based on the FDA approval and the phase 3 randomized trial.[147] Although most of the clinical trial data for rolapitant are in patients receiving HEC, the NCCN Panel feels that prophylactic antiemetic regimens with oral rolapitant are appropriate for patients receiving MEC based on the FDA approval and clinical experience.

Oral rolapitant has an extended half-life and should not be administered at less than 2-week intervals. If oral rolapitant is given on day 1 for either HEC or MEC, no further NK1 RA is needed on days 2 and 3. Similar to the other NK1 RAs, oral rolapitant improves control for delayed emesis compared with traditional antiemetic regimens. Rolapitant does not inhibit or induce CYP3A4; therefore, the dexamethasone dose does not need to be adjusted (see *Dexamethasone* in this Discussion). Rolapitant does, however, inhibit CYP2D6, P-glycoprotein, and breast cancer resistance protein (BCRP); therefore, caution is required when rolapitant is used concomitantly with drugs that are substrates of these enzymes, including thioridazine, pimozide, digoxin, irinotecan, topotecan, methotrexate, and rosuvastatin. The IV formulation of rolapitant was discontinued because of infusion hypersensitivity/anaphylaxis and, therefore, was removed from the NCCN Guidelines (Version 2.2018).

Other Antiemetics

Before the advent of the 5-HT3 antagonists and NK1 RAs, the available antiemetics included phenothiazines,[149] substituted benzamides,[150,151] antihistamines,[152] butyrophenones,[153] corticosteroids,[154-156] benzodiazepines,[157,158] and cannabinoids.[159,160] Based on clinical trial data, the NCCN Panel added olanzapine-containing regimens as another antiemetic option. Combination antiemetic therapy is generally more effective than single-agent therapy. Other agents such as gabapentin have also been evaluated as part of antiemetic regimens.

Dexamethasone

Dexamethasone has been used for many years in combination with other antiemetics. The antiemetic effects of dexamethasone may be due to interactions with the neurotransmitter serotonin and receptor proteins tachykinin NK1 and NK2; it may act directly at the solitary tract nucleus.[161] Before the mid-1990s, studies assessing dexamethasone as an antiemetic agent were characterized by small sample size and variations in efficacy outcomes between the studies. A meta-analysis of 32 studies (published from 1966–1999) was done in 5613 patients; the dose range was 8 to 100 mg of dexamethasone on day 1, and the mean total dose (acute and delayed) was 56 mg.[162] The authors concluded that dexamethasone offered a clear advantage over placebo for protection against anticancer agent–induced emesis in both the acute and delayed phases. There was incremental benefit when adding dexamethasone to both 5-HT3 antagonist-containing regimens and non–5-HT3 antagonist regimens. Although data *suggested* that dexamethasone was superior to 5-HT3 antagonists for protection against delayed emesis, there was a lack of a

strong dose/response relationship. The authors could not rule out a subtle dose/response relationship for total doses less than 20 mg of dexamethasone, but even low doses showed clear efficacy.

The Italian Group for Antiemetic Research conducted two randomized, phase 3 multicenter trials to determine the dose of dexamethasone to be given on day 1 of an antiemetic regimen.[163,164] The first trial was conducted in chemo-naive patients receiving 50 mg/m^2 or more of cisplatin, which is considered HEC.[163] Intravenous dexamethasone day 1 doses were 4, 8, 12, and 20 mg (approximately 130 patients/arm). All patients received the following: 1) ondansetron 8 mg intravenous on day 1; 2) metoclopramide 20 mg oral every 6 hours on days 2 to 4; and 3) dexamethasone 8 mg oral BID on days 2 and 3, followed by 4 mg oral BID on day 4. Complete protection from emesis and nausea was 69.2% and 60.9%; 69.1% and 61.0%; 78.5% and 66.9%; and 83.2% and 71.0% for the 4-, 8-, 12-, and 20-mg dexamethasone doses, respectively. For protection against acute emesis, the 20-mg dose of dexamethasone was statistically significant compared to the 4- and 8-mg doses. However, the 20-mg and the 12-mg doses of dexamethasone were equivalent for protection against acute emesis. The 20-mg dose of dexamethasone was not significantly different from the other doses for protection against acute nausea. Adverse effects and control of delayed emesis and nausea were similar among the four groups.

The second Italian study compared three dosing regimens of dexamethasone on day 1 in patients receiving anthracyclines, cyclophosphamide, or carboplatin, either alone or in combination with other anticancer agents, which previously were considered to be MEC.[164] Note that AC regimens are now considered to be HEC by the NCCN Panel; likewise, carboplatin with an AUC of 4 or more is now considered to be HEC. For the prevention of acute emesis, during the first 24 hours, one of the following dexamethasone regimens was used in combination with 8 mg of intravenous ondansetron: 1) for arm A, 8 mg of intravenous dexamethasone before anticancer agents plus 4 mg oral dexamethasone every 6 hours for 4 doses, starting at the same time as the anticancer agents; 2) for arm B, 24 mg of intravenous single-dose dexamethasone before anticancer agents; or 3) for arm C, 8 mg of intravenous single-dose dexamethasone before anticancer agents. All patients received oral dexamethasone 4 mg BID on days 2 to 5. Complete protection from acute vomiting and nausea was 84.6% and 66.7%, 83.6% and 56.9%, and 89.2% and 61.0% for arms A, B, and C, respectively. Side effects and control of delayed vomiting and nausea were not significantly different among the three groups. The authors concluded that 8 mg of intravenous dexamethasone is the best dose when using dexamethasone in antiemetic regimens for patients receiving anticancer agents with these agents. Of note, 95% of the patients were being treated for breast cancer; thus, most patients were women.

Information from early studies with oral aprepitant-containing regimens suggested that the dose of dexamethasone should be decreased from 20 mg to 12 mg because of a near doubling in the AUC of dexamethasone, presumably due to CYP3A4 inhibition (see *Drug Interactions* in this Discussion). The studies by the Italian Group were done before the NK1 RAs were available, and dose-finding studies for dexamethasone on day 1 in combination with NK1 RAs and 5-HT3 antagonists have not been done.[163,164] This information, along with the previous data showing a lack of a dose/response correlation, was the basis of the NCCN Panel's recommendation of 12 mg of dexamethasone as the day 1 dose for all emetic categories when using any of the recommended antiemetic regimens to simplify the recommendations as described in the next paragraph.

The doses and schedules for dexamethasone in the NCCN Guidelines are mainly based on the doses and schedules used in the clinical trials for

each regimen. However, the NCCN Panel feels that dexamethasone doses may be individualized; lower doses, frequency, or even elimination of dexamethasone on subsequent days may be acceptable based on patient characteristics. Dexamethasone-sparing strategies may be appropriate for patients receiving MEC or non-cisplatin HEC; limiting dexamethasone to day 1 only in these patients may be especially appropriate for patients with few identifiable risk factors for CINV or for those intolerant to corticosteroids (see the NCCN Guidelines for Antiemesis).[107,165-170] Dexamethasone is associated with side effects, such as insomnia.

Recently, the NCCN Panel simplified the dosing for dexamethasone for the intravenous HEC and MEC regimens. For the 3-drug prophylactic olanzapine regimen—olanzapine plus palonosetron plus dexamethasone—for HEC and MEC, the dose of dexamethasone was decreased to 12 mg orally (or intravenously) for day 1, because all the other antiemetic regimens use this dexamethasone dose on day 1. Previously, the panel had recommended a dexamethasone dose of 20 mg orally (or intravenously) on day 1 in the 3-drug olanzapine regimen. For all the HEC regimens, the panel also simplified the dosing for delayed dexamethasone to 8 mg orally (or intravenously) daily on days 2 to 4 (previously, some of the HEC regimens had used twice-daily dosing of dexamethasone). The NCCN Panel recommends that if patients cannot tolerate dexamethasone, it can be replaced with olanzapine.

When dexamethasone is used with palonosetron for MEC, a randomized trial suggests that the dose of dexamethasone can be decreased to 8 mg on day 1 and also eliminated on days 2 to 3.[107] A similar phase 3 trial assessed palonosetron with dexamethasone on day 1 only versus palonosetron (day 1) with dexamethasone on days 1 to 3 in women receiving MEC regimens.[169] For women receiving dexamethasone on day 1 only (n = 166), the overall CR rates were 67.5% versus 71.1% for those receiving dexamethasone on days 1 to 3 (n = 166; difference -3.6% [95% CI, -13.5–6.3]). There was no difference in CR rates between the two regimens during the acute (0–24 hours postchemotherapy; 88.6% vs. 84.3%; $P = .262$) and delayed phases (days 2–5; 68.7% vs. 77.7%; $P = .116$).[169]

Olanzapine

Olanzapine is an atypical antipsychotic agent that is also useful as an antiemetic agent; it is an antagonist of multiple receptors involved in CINV, including dopamine, serotonin, histamine, and acetylcholine-muscarine.[22] A 3-drug antiemetic regimen with olanzapine, dexamethasone, and palonosetron is effective for preventing acute and delayed emesis as described in the following sections.[22,171-179] An olanzapine-containing 4-drug antiemetic regimen is also effective for preventing acute and delayed emesis.[180] A Cochrane analysis also reported that olanzapine regimens are effective.[181] The NCCN Panel recommends (category 1) olanzapine-containing 3-drug or 4-drug antiemetic regimens for both HEC and MEC based on the clinical trial data as described in the following sections.[37] Olanzapine can be substituted for dexamethasone if patients cannot tolerate dexamethasone (eg, diabetics).

Common side effects with olanzapine include postural hypotension, anticholinergic side effects, fatigue, and sedation.[182] Olanzapine should be used with caution in elderly patients (see boxed warning/label indication regarding death in patients with dementia-related psychosis and additional warnings and precautions about type II diabetes and hyperglycemia).[183] Data suggest that a 5-mg dose of olanzapine may be considered, especially for elderly or oversedated patients.[184-188] For the 2020 update (Version 1), the NCCN Panel added a caveat that 2.5 mg of olanzapine can be considered if patients have excessive sedation with the 5-mg dose. In addition, the panel deleted the contraindication against combining

parenteral olanzapine with parenteral benzodiazepine because parenteral olanzapine is not recommended in the NCCN Guidelines.[189]

Three-Drug Regimen

A 3-drug antiemetic regimen with olanzapine, dexamethasone, and palonosetron is effective for preventing acute and delayed emesis based on phase 3 trials, phase 2 trials, and a meta-analysis.[22,171-179] A randomized phase 3 trial evaluated the effectiveness of an olanzapine (10 mg oral days 1–4) regimen versus an oral aprepitant (125 mg oral day 1, 80 mg oral days 2, 3) regimen with dexamethasone 8 mg on days 2 to 4 for preventing acute and delayed emesis in patients (N = 251) receiving HEC (cisplatin, or AC regimens); both treatment arms included palonosetron (0.25 mg intravenous) and dexamethasone administered on day 1.[178] The CR (no emesis, no rescue) rate was similar between the olanzapine and oral aprepitant regimens, both during the acute (97% vs. 87%) and delayed (77% vs. 73%) periods. The proportion of patients without nausea was similar for the acute period (87% in each study arm), but the olanzapine regimen was associated with a higher rate of nausea control during the delayed period (69% vs. 38%) compared with the oral aprepitant regimen.[178] A systematic review summarized the phase 1 and 2 studies of olanzapine for preventing acute and delayed emesis.[22] Across four studies (201 patients), the CR rate was 97.2%, 83.1%, and 82.8 % for the acute, delayed, and overall phases, respectively. Other studies have also shown the value of olanzapine for delayed, refractory, and breakthrough emesis and nausea.[173-176,187]

The NCCN Panel recommends (category 1) a prophylactic olanzapine-containing 3-drug antiemetic regimen for both HEC and MEC based on the phase 3 and phase 2 trials.[22,171-179] As previously mentioned, the NCCN Panel decided to decrease the dose of dexamethasone to 12 mg orally (or intravenously) on day 1 for the 3-drug antiemetic regimen with olanzapine/palonosetron/dexamethasone, because all the other antiemetic regimens use a dexamethasone dose of 12 mg orally (or intravenously) on day 1. Previously, the panel had recommended a dexamethasone dose of 20 mg orally (or intravenously) on day 1 in the 3-drug olanzapine regimen based on the clinical trial data.[178] The panel also agreed that palonosetron should be used in the 3-drug olanzapine regimen; no data are available to support substituting any of the other 5-HT3 antagonists.

Four-Drug Regimen

A phase 3 randomized trial assessed adding olanzapine or placebo to an antiemetic regimen of oral aprepitant or fosaprepitant, a 5-HT3 antagonist, and dexamethasone for patients receiving HEC.[180] The 4-drug regimen with olanzapine increased the CR rate (no emesis, no rescue) compared with placebo during three time periods (<24 hours after chemotherapy, 25–120 hours, and the overall 120 hours: 86% vs. 65% [$P < .001$], 67% vs. 52% [$P = .007$], and 64% vs. 41% [$P < .001$], respectively). In addition, more patients receiving the 4-drug olanzapine regimen had no chemotherapy-induced nausea compared with placebo during the three time periods (<24 hours after chemotherapy, 25–120 hours, and 120 hours: 74% vs. 45% [$P = .002$], 42% vs. 25% [$P = .002$], and 37% vs. 22% [$P = .002$], respectively). FOND-O, a phase 3 randomized trial, assessed adding olanzapine to fosaprepitant, ondansetron, and dexamethasone in patients receiving HEC and hematopoietic transplantation.[40] The CR was 55% in patients receiving the 4-drug olanzapine regimen versus 26% in those receiving the 3-drug regimen in the overall phase ($P = .03$); the CR was 60.8% versus 30%, respectively, in the delayed phase ($P = .001$).

Based on the trial by Navari and colleagues, the NCCN Panel recommends (category 1) the 4-drug olanzapine antiemetic regimen for HEC.[180] For the 2020 update (Version 1), the NCCN Panel now recommends that the 4-drug olanzapine regimen is also preferred (category 1) for patients with HEC based on trial data and clinical

experience.[180] In addition, clinicians can consider switching patients to the 4-drug olanzapine regimen if patients have significant emesis after the first cycle of HEC when receiving other antiemetic regimens such as: 1) NK1 RA-containing regimens; or 2) the 3-drug olanzapine regimen (olanzapine/dexamethasone/palonosetron).[37] The panel agreed that any NK1 RA (ie, not just fosaprepitant or oral aprepitant) could be used in the 4-drug HEC regimen on day 1 (olanzapine/NK1 RA/5-HT3/dexamethasone), because all of the NK1 RAs are effective if the appropriate dose is used. Thus, aprepitant injectable emulsion, oral rolapitant, or NEPA may be used in the 4-drug olanzapine regimen on day 1; however, none of these agents is continued on days 2 to 4.

Treatment Issues

These NCCN Guidelines include a section on pharmacologic considerations for the different antiemetics describing: 1) the major classes of antiemetics; 2) clinical pearls associated with the different types of agents; and 3) possible drug-drug or drug-disease interactions among the different antiemetics, although these drug interactions are less likely to occur with short-term use of antiemetic agents (see *Pharmacologic Considerations for Antiemetic Prescribing* in the NCCN Guidelines for Antiemesis). In contrast to other NCCN Guidelines in which most of the recommendations are category 2A, many of the recommendations for antiemetic management regimens are classified as category 1, reflecting the large number of RCTs that have focused on antiemetic management.

Principles of Emesis Control

The goal of emesis control is to prevent nausea and/or vomiting (see *Principles of Emesis Control for the Cancer Patient* in the NCCN Guidelines for Antiemesis). Prophylactic antiemetic regimens should be chosen based on the drug with the highest emetic risk in the anticancer agent regimen, previous experience with antiemetics, and patient-specific risk factors.[46] Patients need to be protected throughout the entire period of risk, which lasts for at least 3 days for HEC and 2 days for MEC after the last dose of an anticancer agent. In addition to using antiemetic regimens, patients can adjust their eating habits and adopt other lifestyle measures that may alleviate nausea and/or vomiting (see *Eating Hints: Before, During, and After Cancer Treatment* from the National Cancer Institute).[190] Suggestions include eating small frequent meals, food that is easy on the stomach, full liquid foods, and food at room temperature; patients can also avoid foods that make them feel nauseated.

Prevention of Acute and Delayed Emesis

To prevent acute emesis, antiemetic therapy should start before the administration of anticancer agents and then should cover the first 24 hours. In the NCCN Guidelines for Antiemesis, the specific prophylactic antiemetic regimens are described for patients receiving highly emetogenic parenteral drugs, moderately emetogenic parenteral drugs, low emetogenic parenteral drugs, and minimally emetogenic parenteral drugs. Prophylactic antiemetic regimens for oral chemotherapeutic agents are also described in the NCCN Guidelines. This section discusses emesis prevention before and after anticancer agent administration rather than primary treatment for ongoing emesis.

Decreasing Acute Emesis

The NCCN Guidelines specify different prophylactic antiemetic regimens for cancer patients receiving anticancer agents of different emetogenic potential (ie, high, moderate, low, minimal). Prophylactic antiemetics should be administered before anticancer agents. The recommendations for prophylactic antiemetic treatment include drug dosages. The guidelines reflect accumulating experience with the different antiemetic agents, demonstrating their effectiveness in a range of doses. As previously mentioned, if patients receive prophylactic antiemetic regimens, emesis will be decreased but not completely prevented. More than 90% of patients receiving HEC without antiemetic prophylaxis will have episodes

of vomiting. However, if patients receive prophylactic (preventive) antiemetic regimens before treatment with HEC, then only about 30% of these patients will vomit.[7,9,10]

Highly emetogenic parenteral drugs in the NCCN Guidelines include carboplatin (AUC ≥ 4), carmustine (>250 mg/m^2), cisplatin (any dose), cyclophosphamide (>1500 mg/m^2), dacarbazine (any dose), doxorubicin (≥60 mg/m^2), epirubicin (>90 mg/m^2), ifosfamide (≥2 g/m^2 per dose), mechlorethamine (any dose), streptozocin (any dose), or AC combination regimens at any dose (eg, cyclophosphamide plus either doxorubicin or epirubicin).

The NCCN Panel changed the emetogenic classification for carboplatin a few years ago. When dosed at an AUC of 4 or more, carboplatin is now considered highly emetogenic; carboplatin at an AUC of less than 4 is now considered moderately emetogenic. The NCCN Panel revised the classification of carboplatin based on data suggesting that carboplatin, while less emetogenic than cisplatin, is perhaps on the higher end of emetogenic potential within the MEC classification.[191] Data show it is beneficial to add an NK1 RA to the 2-drug regimen of 5-HT3 antagonist and dexamethasone for the prevention of CINV associated with carboplatin-based regimens.[147,191-195] All of the commercially available NK1 RAs have an FDA-approved indication for MEC, but older versions of NCCN Guidelines supported the addition of an NK1 RA only for select patients receiving MEC with additional CINV risk factors or for those who had failed previous therapy with a corticosteroid and 5-HT3 antagonist alone. The panel did not want to create a “carboplatin subset” within the MEC classification; therefore, carboplatin at an AUC of 4 or more was escalated to the HEC classification; any of the regimens for HEC are recommended for these patients.

Several drugs listed as moderately emetogenic in the NCCN Guidelines may be highly emetogenic in certain patients (eg, carboplatin [AUC < 4], carmustine [≤250 mg/m^2], cyclophosphamide [≤1500 mg/m^2], dactinomycin, daunorubicin, doxorubicin [<60 mg/m^2], epirubicin [≤90 mg/m^2], idarubicin, ifosfamide [<2 g/m^2], irinotecan, methotrexate [≥250 mg/m^2], oxaliplatin, trabectedin). AC-based regimens were reclassified in 2011 as highly emetogenic in the ASCO antiemetic guidelines.[92]

Antiemetic Regimens for Parenteral HEC

The NCCN Guidelines recommend 3-drug and 4-drug antiemetic regimen options (all are category 1) for patients receiving HEC, including 1) NK1 RA, a 5-HT3 RA, and dexamethasone; 2) olanzapine, palonosetron, and dexamethasone; or 3) olanzapine, an NK1 RA, a 5-HT3 RA, and dexamethasone.[178,180] For the 2020 update, the NCCN Panel voted that the 4-drug olanzapine regimen (olanzapine, NK1 RA, 5-HT3 RA, dexamethasone) is the preferred regimen for patients at high risk for emesis from parenteral anticancer agents (see *Olanzapine* in this Discussion). If needed, lorazepam, an H2 blocker, or a proton pump inhibitor may also be added (alone or in any combination) to all of these regimens.[35,41,124] Note that the regimens and doses are often modified on days 2 to 4 after anticancer agents.

Although it is not recommended as a single agent, lorazepam is a useful adjuvant because it decreases anxiety.[41,158] Lorazepam is also recommended for patients who are at risk for anticipatory nausea and/or vomiting (see *Anticipatory Emesis Prevention/Treatment* in the NCCN Guidelines for Antiemesis). Antacid therapy (eg, proton pump inhibitors, H2 blockers) should be considered if patients have dyspepsia, because patients sometimes have difficulty discriminating heartburn from nausea. If appropriate, lorazepam (0.5–2 mg every 6 hours on days 1–4; either oral, intravenous, or sublingual) may be used with each of these regimens.

For parenteral HEC, aprepitant is used at an oral dosage of 125 mg on day 1 and then 80 mg on days 2 and 3. When given with aprepitant, dexamethasone is used at a dosage of 12 mg on day 1; the

dexamethasone dose can be oral or intravenous. Note that aprepitant injectable emulsion or intravenous fosaprepitant may be used instead of oral aprepitant on day 1 only. As previously discussed, a phase 3 randomized trial suggested that palonosetron is preferred over granisetron in combination with dexamethasone for HEC.[72] This trial has been criticized because: 1) the control arm was not adequately dosed; thus, the trial "stacked the deck" in favor of palonosetron; 2) a larger non–FDA-approved dose of palonosetron was used (ie, 0.75 mg intravenous); and 3) aprepitant was not used in this study. Therefore, the NCCN Guidelines do not recommend palonosetron as the preferred 5-HT3 antagonist for HEC. As previously noted, an alternative antiemetic regimen in the setting of parenteral HEC includes olanzapine (5–10 mg oral days 1–4), palonosetron (0.25 mg intravenous day 1 only), and dexamethasone (12 mg intravenous day 1 only).[178]

A Canadian meta-analysis suggested that the use of 5-HT3 antagonists (ie, ondansetron) on days 2 to 4 to prevent delayed emesis was not cost-effective; however, ondansetron (when used alone) did protect against delayed emesis in this meta-analysis.[196] Palonosetron was not assessed in these studies. The NCCN Guidelines do not recommend a 5-HT3 antagonist for the prevention of CINV on days 2 to 4 for HEC.

Antiemetic Regimens for Parenteral MEC

The NCCN Guidelines recommend 2-drug and 3-drug antiemetic regimens for parenteral MEC, including: 1) dexamethasone and a 5-HT3 antagonist with NK1 RAs, such as aprepitant (oral or injectable emulsion), fosaprepitant, netupitant, fosnetupitant, or oral rolapitant; 2) olanzapine, palonosetron, and dexamethasone; or 3) dexamethasone and a 5-HT3 antagonist (palonosetron or subcutaneous granisetron extended-release injection are preferred). If needed, lorazepam, an H2 blocker, or a proton pump inhibitor may be added (alone or in any combination) to these regimens.[7] Netupitant (or fosnetupitant) is only available combined with palonosetron (NEPA) and not as a single agent. As previously mentioned, an NK1 RA or olanzapine should be added (to dexamethasone and a 5-HT3 antagonist regimen) for select patients with additional risk factors or failure of previous therapy with a corticosteroid and 5-HT3 antagonist alone. These additional risk factors include younger age; female sex; anxiety and/or high pretreatment expectation of nausea and/or vomiting; and history of CINV, motion sickness, morning sickness during pregnancy, and little or no alcohol use.[122] This list of risk factors was updated for the 2020 guidelines. Intravenous fosaprepitant or aprepitant injectable emulsion may be substituted for oral aprepitant on day 1 only. The NCCN Guidelines recommend the use of 5-HT3 antagonists as one of several options to prevent delayed emesis for MEC. Any one of the 5-HT3 antagonists can be used in the first regimen for day 1; however, preferred 5-HT3s include palonosetron or subcutaneous granisetron extended-release injection when an NK1 RA is not included, as previously mentioned.[72,93]

Antiemetic Regimens for Parenteral Low Emetic Risk Anticancer Agents

The single-agent antiemetic regimens for low emetogenic risk parenteral anticancer agents include dexamethasone, prochlorperazine, metoclopramide, or orally administered 5-HT3 antagonists, such as granisetron, ondansetron, or dolasetron (see the NCCN Guidelines for Antiemesis). Lorazepam, an H2 blocker, or a proton pump inhibitor may also be added (alone or in any combination) to all of these agents.[7] When using prochlorperazine or metoclopramide, patients should be monitored for dystonic reactions.[197-199] Diphenhydramine can be used for the treatment of dystonic reactions.[200,201] Benztropine may be used in patients who are allergic to diphenhydramine.[198] For the 2020 update (Version 1), the NCCN Panel added amantadine as an option for drug-induced dystonic reactions in patients who are intolerant of anticholinergic agents.[202-205]

Antiemetic Regimens for Oral Anticancer Agents

The emetogenic potential of oral anticancer agents is shown in the NCCN Guidelines, which is updated every year with the new agents. Oral antiemetic prophylaxis is recommended for the following oral agents, which are of high or moderate emetic risk: altretamine, avapritinib, binimetinib, busulfan (≥4 mg/day), ceritinib, crizotinib, cyclophosphamide (≥100 mg/m^2/day), dabrafenib, enasidenib, encorafenib, estramustine, etoposide, lenvatinib, lomustine (single day), midostaurin, mitotane, niraparib, olaparib, procarbazine, rucaparib, selinexor, and temozolomide (>75 mg/m^2/day or ≤75 mg/m^2/day with concurrent radiotherapy). For high or moderate emetic risk oral anticancer agents, recommended prophylaxis includes single-agent antiemetic therapy with granisetron, ondansetron, or dolasetron. For low or minimal emetic risk oral anticancer agents, recommended oral agents are given on an as-needed basis only (ie, PRN) and include granisetron, ondansetron, dolasetron, metoclopramide, or prochlorperazine; the NCCN Panel previously deleted haloperidol. Lorazepam, an H2 blocker, or a proton pump inhibitor may also be added (alone or in any combination) if needed to all of these high/moderate or low/minimal emetic risk regimens.[7] Some patients receiving oral anticancer agents of low/minimal emetogenicity may experience nausea and/or vomiting; these patients should be escalated to the next higher level of antiemetic therapy in future cycles of anticancer agents.

Decreasing Delayed Nausea and/or Emesis

Delayed Nausea

Many antiemetic regimens are very useful for decreasing vomiting but are less useful for decreasing delayed nausea that many patients experience when taking emetogenic anticancer agents.[12,23,27,46] Patients rank nausea as more of a problem than vomiting.[12] Data suggest that oral rolapitant and netupitant are effective at decreasing delayed nausea.[141,143,147,148] Palonosetron and subcutaneous granisetron extended-release injection are the preferred 5-HT3 antagonists for preventing delayed nausea associated with MEC.

A phase 3 randomized trial assessed adding olanzapine or placebo to an antiemetic regimen of fosaprepitant or oral aprepitant, a 5-HT3 antagonist, and dexamethasone for patients receiving HEC.[180] More patients receiving the 4-drug regimen with olanzapine had no anticancer agent–induced nausea compared with placebo during the delayed time period (ie, 25–120 hours, 42% vs. 25% [*P* = .002]). Nausea was also reduced with the 4-drug regimen with olanzapine during the acute phase and the overall time period compared with placebo. The 4-drug regimen with olanzapine increased the CR rate (no emesis, no rescue) during the delayed time period compared with placebo (67% vs. 52%; *P* = .007). The 3-drug olanzapine/dexamethasone/palonosetron regimen was associated with a higher rate of nausea control during the delayed period (69% vs. 38%) compared with the 3-drug oral aprepitant regimen (with palonosetron and dexamethasone).[178] However, the proportion of patients without nausea was similar for the acute period (87% in each study arm).[178] Therefore, olanzapine seems especially effective for decreasing nausea.

Delayed Emesis

The best management for delayed emesis is prevention.[206] A survey among oncology nurses found that there is low adherence (only 25%) to antiemetic guidelines for preventing delayed emesis.[207] For HEC, the prophylactic antiemetic treatment on days 2 to 4 depends on which antiemetics were used on day 1. Fosaprepitant, aprepitant injectable emulsion, oral rolapitant, granisetron extended-release injection, granisetron transdermal patch, palonosetron, or NEPA are used on day 1 only, because they are effective for an extended period of time. If oral olanzapine was used on day 1 for HEC, then oral olanzapine is continued on days 2 to 4. If oral aprepitant was used on day 1 for HEC, then oral aprepitant is continued on days 2 and 3. Dexamethasone may be

continued on days 2 to 4 for HEC, depending on the regimen. However, 5-HT3 antagonists are given on day 1 only for HEC. There are several possible HEC antiemetic regimens on days 2 to 4, including: 1) oral aprepitant (if used on day 1) with dexamethasone and with or without olanzapine; or 2) olanzapine only. If needed, each of these regimens may also include lorazepam, an H2 blocker, or a proton pump inhibitor (alone or in any combination).[7]

The antiemetic regimens in the NCCN Guidelines include different options on days 2 to 3 for MEC, including single-agent therapy.[35,41,206] Antiemetic treatment on days 2 to 3 depends on which antiemetic regimens were used on day 1. If oral aprepitant or olanzapine was used on day 1, then oral aprepitant or olanzapine is continued on days 2 and 3. However, granisetron extended-release injection, granisetron transdermal patch, palonosetron, aprepitant injectable emulsion, fosaprepitant, oral rolapitant, or NEPA are not given on days 2 and 3.[74] There are several possible MEC antiemetic regimens for days 2 to 3, including: 1) oral aprepitant (if used on day 1) with or without dexamethasone; 2) dexamethasone only; 3) ondansetron, granisetron, or dolasetron only (if no NK1 RA, granisetron extended-release injection, granisetron transdermal patch, or palonosetron was given on day 1); or 4) olanzapine only.[206] If needed, each of these regimens may also include lorazepam, an H2 blocker, or a proton pump inhibitor (alone or in any combination).[7] The doses are decreased when used on days 2 to 3 for oral aprepitant (80 mg oral) and dexamethasone (8 mg oral or intravenous) compared with the doses given on day 1. However, the dose of olanzapine is not decreased on days 2 and 3.

Breakthrough Nausea and/or Vomiting Treatment

Breakthrough nausea or emesis presents a difficult situation, because refractory ongoing nausea and/or vomiting is often challenging to reverse (see *Principles for Managing Breakthrough Emesis* in the NCCN Guidelines for Antiemesis). Generally, it is much easier to prevent nausea and/or vomiting than to treat it, which is why the NCCN Guidelines recommend prophylactic antiemesis regimens. Routine around-the-clock administration of antiemetics is recommended to prevent emesis, rather than PRN (as needed) dosing. The general principle of breakthrough treatment is to add an additional agent as needed from a different drug class.[35] Some patients may require several agents each with a different mechanism of action. The oral route may not be feasible because of ongoing vomiting; therefore, rectal, topical, subcutaneous, or intravenous therapy is often required. Multiple concurrent agents, perhaps in alternating schedules or by alternating routes, may be necessary. Another option is to consider changing from the current NK1-containing regimen to an olanzapine-containing regimen, or vice versa, prior to the next cycle of anticancer agents. Olanzapine is possibly more effective than NK1-antagonist–containing regimens for preventing nausea.[22,178,179] Switching to a different 5-HT3 RA and/or NK1 RA with a different pharmacokinetic/pharmacodynamic profile is another option, although there is only anecdotal evidence that this may be helpful.

In a randomized phase 3 trial, the effectiveness of olanzapine (10 mg/day oral for 3 days) as treatment for breakthrough emesis was compared with metoclopramide in patients treated with HEC who developed breakthrough emesis or nausea despite antiemetic prophylaxis with palonosetron, dexamethasone, and fosaprepitant (n = 108 evaluable).[208] Patients were observed for emesis and nausea during the 72 hours after treatment with olanzapine or metoclopramide. During this observation period, more patients had no emesis (70% vs. 31%; $P < .01$) and no nausea (68% vs. 23%; $P < .01$) with olanzapine than with metoclopramide.[208] Thus, olanzapine was more effective in controlling breakthrough emesis and nausea compared with metoclopramide in this patient population. The MASCC/ESMO and ASCO Guidelines recommend olanzapine for breakthrough emesis.[36,209] The NCCN Panel recommends olanzapine (category 1; preferred) for breakthrough emesis if olanzapine was not

used on days 1 to 4 as part of a prophylactic regimen. This category 1 recommendation is based on the magnitude of superiority of olanzapine over metoclopramide in the randomized phase 3 trial.[208] Other recommended treatment options for breakthrough emesis may be added to the current antiemetic regimen such as metoclopramide, haloperidol, scopolamine transdermal patch, corticosteroids, cannabinoids, and lorazepam. For the 2020 update (Version 1), the NCCN Panel added a caveat that haloperidol may increase the QT interval of the ECG.

Dronabinol and nabilone are cannabinoids that are approved by the FDA for refractory nausea and vomiting when patients have not responded to conventional antiemetics. Note that dronabinol oral solution (5 mg/mL) and dronabinol capsules are not bioequivalent. Dronabinol oral solution has greater oral bioavailability than dronabinol capsules (2.1 mg oral solution = 2.5 mg capsules).[210] Recommended starting doses are dronabinol oral solution (4.2 mg/m^2) or dronabinol capsules (5 mg/m^2) both given 3 to 4 times daily. Lower doses are recommended in elderly patients.

Before administering the next cycle of anticancer agents, the patient should be reassessed for other possible reasons for breakthrough emesis with the current cycle that are not related to anticancer agents, including brain metastases, electrolyte abnormalities, tumor infiltration of the bowel or other GI abnormality, excessive secretions (eg, seen in patients with head and neck cancer), and other comorbidities (see *Principles for Managing Breakthrough Emesis* and *Principles of Emesis Control for the Cancer Patient* in the NCCN Guidelines for Antiemesis). Adequate hydration or fluid repletion should be ensured, and any possible electrolyte abnormalities should be assessed and corrected. If the antiemetic regimen (both on day 1 and days 2–4) did not protect the patient during the present cycle, the antiemetic regimen should be assessed and alternatives should be considered before the next cycle of anticancer agents (see *Principles for Managing Breakthrough Emesis* in the NCCN Guidelines for Antiemesis). Because patients sometimes have difficulty discriminating heartburn from nausea, addition of antacid therapy should be considered, such as proton pump inhibitors and H2 blockers.

Radiation-Induced Nausea and/or Vomiting

Antiemetic prophylaxis for RT-induced nausea and/or vomiting is based on the site of RT and whether it is combined with anticancer agents.[37,38,211,212] When RT is combined with anticancer agents, prophylaxis is dictated by the emetogenic potential of the anticancer agent regimen.[213] ASCO and MASCC/ESMO guidelines state that total body irradiation is associated with the highest risk for emesis and that upper abdominal RT is associated with moderate risk.[37,38,214] A meta-analysis suggests that 5-HT3 antagonists are the preferred agents for preventing RT-induced vomiting.[215]

Patients undergoing RT to the upper abdomen may receive antiemetic prophylaxis with oral ondansetron or oral granisetron, with or without oral dexamethasone.[10,38] A randomized trial compared oral ondansetron with placebo in patients receiving daily fractionated radiotherapy including the abdomen. In this study, 67% of patients given ondansetron had complete control of emesis compared with 45% of patients who received placebo (P < .05).[216] A randomized trial showed that the addition of oral dexamethasone (4 mg daily) to the ondansetron regimen decreases emesis and nausea, although the effect was modest.[217] Patients receiving ondansetron/dexamethasone had better complete control of emesis (23% vs. 12%; P = .02) and a lower average nausea score (0.28 vs. 0.39; P = .03) compared with those receiving ondansetron alone. Another randomized trial in patients receiving radiotherapy to the upper abdomen found that oral granisetron decreased emesis and nausea compared with placebo.[218]

The NCCN Panel recommends that patients undergoing total body irradiation or upper abdomen RT receive antiemetic prophylaxis with either oral ondansetron or oral granisetron; either agent can be given with or without oral dexamethasone.[10,38,219] Treatment of breakthrough RT-induced emesis is similar to anticancer agent–induced emesis. Patients who experience breakthrough nausea and/or vomiting may be treated with a different class of agent, or with ondansetron or granisetron if they did not receive primary prophylaxis (see *Breakthrough Treatment for Chemotherapy-Induced Nausea/Vomiting* in the NCCN Guidelines for Antiemesis).

Anticipatory Nausea and/or Vomiting

About 20% of patients develop anticipatory nausea and/or vomiting.[220] However, the rate of anticipatory nausea and/or vomiting appears to be decreasing with current use of more effective antiemetic regimens compared with older studies.[10] The most effective way to treat anticipatory nausea and/or vomiting is to prevent it by using optimal antiemetic therapy during every cycle of treatment.[35,37,221,222] Behavioral therapy has been used in patients with anticipatory nausea and/or vomiting.[37,223-228] Systematic desensitization may also be helpful.[224] Hypnosis with guided imagery is another behavioral technique that has shown some success in treating this condition.[225]

The antianxiety agent lorazepam has been combined with antiemetics for anticipatory nausea and/or vomiting.[222,229,230] The usual starting dose of lorazepam for anxiety is 0.5 to 2 mg orally, beginning on the night before treatment and then repeated the next day 1 to 2 hours before treatment begins with anticancer agents. The usual starting dose of lorazepam is 0.5 mg orally for treatment of anxiety in patients who are elderly, those with debilitating disease, and those with advanced liver disease (see prescribing information). This dose may be gradually increased if needed. Note that the elderly are especially sensitive to the effects of benzodiazepines. The dose should be gradually reduced when decreasing or discontinuing lorazepam therapy.

The NCCN Panel recommends behavioral therapy options for anticipatory nausea and/or vomiting including yoga, cognitive distraction, relaxation exercises (eg, music therapy), and biofeedback (see the NCCN Guidelines for Antiemesis). The panel also recommends lorazepam and acupuncture. Lorazepam should be used with caution in patients receiving scheduled opioids because of the increased risk of respiratory depression. Previously, the NCCN Panel deleted alprazolam, because rebound anxiety is more prevalent with alprazolam than with lorazepam. The NCCN Guidelines also recommend that patients avoid strong smells that may precipitate symptoms.

Multiday Emetogenic Anticancer Agent Regimens

Patients receiving multiday anticancer agents are at risk for both acute and delayed nausea and/or vomiting based on the emetogenic potential of the individual anticancer agents and their sequence.[35,231-235] It is difficult to recommend a specific antiemetic regimen for each day, especially because acute and delayed emesis may overlap after the initial day of the anticancer therapy until the last day. The period of risk for delayed emesis following completion of the anticancer agents also depends on the specific regimen and the emetogenic potential of the last anticancer agent administered in the regimen. For multidrug regimens, antiemetic therapy should be selected based on the drug with the highest emetic risk.[37] General principles for managing multiday emetogenic chemotherapy regimens recommended by the NCCN Panel are described in the algorithm (see *Principles of Managing Multiday Emetogenic Chemotherapy Regimens* in the NCCN Guidelines for Antiemesis).

A meta-analysis reported that a 3-drug regimen with 5-HT3 RA, oral aprepitant, and dexamethasone was useful for decreasing emesis with

multiday cisplatin regimens.[236] For antiemetic prophylaxis of multiday emetogenic anticancer agent regimens (eg, cisplatin-containing regimens), the combination of a 5-HT3 antagonist with dexamethasone was previously recommended in the 2011 MASCC/ESMO guidelines.[10,35] The NCCN Guidelines and 2017 MASCC/ESMO guidelines currently recommend a 3-drug regimen. For single-day chemotherapy regimens, category 1 evidence is available for aprepitant, aprepitant injectable emulsion, fosaprepitant, netupitant, fosnetupitant, or rolapitant administered in combination with a 5-HT3 RA and corticosteroid. The clinical trial data to support these recommendations are described in the following sections.

Dexamethasone

Dexamethasone should be administered once daily either orally or intravenously for every day of MEC or HEC and continued for 2 to 3 days for anticancer agent regimens that are likely to cause significant delayed emesis. However, dexamethasone should not be added when the anticancer regimen already includes a corticosteroid. The NCCN Panel does not recommend the use of corticosteroids in antiemetic regimens for 3 to 5 days before and 90 days after CAR T-cell therapies, because corticosteroids may decrease the persistence of the CAR T-cell population.[237,238] For the 2020 update (Version 1), the NCCN Panel deleted the caveat that corticosteroids as antiemetics should be avoided when using immune checkpoint inhibitors—–such as ipilimumab, cemiplimab, nivolumab, atezolizumab, pembrolizumab, avelumab, or durvalumab—–because data are inconclusive in this setting.[239] All of these immune checkpoint inhibitors are of minimal emetic risk. Dexamethasone-sparing strategies or replacing dexamethasone with olanzapine are options for patients who cannot tolerate corticosteroids.[166,167]

5-HT3 Antagonists

For multiday anticancer regimens, a 5-HT3 antagonist should be administered each day before the first dose of MEC or HEC. Intravenous palonosetron, subcutaneous granisetron, or transdermal granisetron may be used before the start of a 3-day anticancer regimen instead of multiple daily doses of oral or intravenous 5-HT3 antagonists.[240,241] It is not known whether repeat dosing with subcutaneous granisetron for multiday regimens would be effective. Repeat dosing of palonosetron (0.25 mg intravenous) is likely to be safe, based on the dose-ranging phase 2 trial and the three phase 3 trials using palonosetron as a single fixed dose (0.75 mg intravenous).[71,73,74,242] Compared to the approved dose of palonosetron of 0.25 mg intravenous, these higher doses were not associated with significantly different adverse events.

The need for repeat dosing with palonosetron, either daily or less frequently, in the setting of multiday anticancer regimens is not yet known. In one study, patients receiving highly emetogenic multiday cisplatin-based therapy for testicular cancer (N = 41) received multiday dosing of palonosetron (0.25 mg intravenous on days 1, 3, and 5) and dexamethasone, which prevented nausea and emesis in most patients on days 1 to 5 (51%) and on days 6 to 9 (83%); the most common adverse events were mild headache and constipation.[243] A study assessed palonosetron given for 1, 2, or 3 days in combination with dexamethasone for patients receiving multiday high-dose anticancer regimens prior to stem cell transplantation for multiple myeloma (N = 73); during the 7-day emesis prevention period, about 40% to 45% of patients had no emesis (with no differences observed between palonosetron treatment groups), and no serious adverse events were reported. However, even among the patients who received either 2 or 3 days of palonosetron, only 20% had a CR (ie, emesis free without rescue medication).[121] Another study found that a palonosetron/dexamethasone regimen appeared to be more effective for multiday anticancer therapy than an ondansetron/dexamethasone

regimen; patients received a second dose of palonosetron for breakthrough emesis, which was effective in 67% of patients who experienced nausea or vomiting.[240] A review also cited the value of palonosetron for patients receiving multiday anticancer therapy.[244] Further studies are needed to define whether a need exists for repeat dosing of palonosetron in the setting of multiday anticancer therapy.

NK1 RAs

The potential role of NK1 RAs in the antiemetic management of multiday anticancer therapy has been investigated in several studies.[148,209,245-247] In a randomized phase 3 trial, the efficacy of adding oral aprepitant (vs. placebo) to an antiemetic regimen with a 5-HT3 antagonist and dexamethasone was evaluated in patients with testicular cancer undergoing 2 cycles of a 5-day cisplatin combination therapy regimen (n = 69 evaluable).[245] Patients were randomized to receive oral aprepitant (125 mg oral day 3, 80 mg oral days 4–7) or placebo, combined with a 5-HT3 antagonist (days 1–5) and dexamethasone (20 mg days 1, 2) during the first cycle, and then crossed over to the opposite antiemetic regimen during the second cycle of anticancer therapy. Thus, patients served as their own controls after receiving either oral aprepitant or placebo for cycle 1. Palonosetron was excluded from the options for 5-HT3 antagonists due to its longer half-life.[245] The primary endpoint of the study was CR (no emetic episodes and no rescue medication) during the overall study period (days 1–8). The CR rate for the overall study period was significantly higher with oral aprepitant compared with placebo (42% vs. 13%; $P < .001$). The CR rates were also higher with oral aprepitant during the acute phase (days 1–5; 47% vs. 15%; $P < .001$) and delayed phase (days 6–8; 63% vs. 35%; $P < .001$).[245] No statistically significant differences were observed between treatment regimens in terms of nausea (based on patient-reported visual analog scale). Importantly, no increase in toxicity with oral aprepitant compared with placebo was reported.[245]

The addition of oral aprepitant to granisetron and dexamethasone was evaluated in patients receiving multiday HEC and MEC (N = 78). In this study, the 3-drug antiemetic regimen was given during anticancer therapy; oral aprepitant and dexamethasone were given for an additional 2 days following anticancer therapy.[247] A CR (during the time period from day 1 until 5 days after anticancer therapy) was observed in 58% and 73% of patients who received antiemetic regimens for HEC and MEC, respectively.[247] In a multicenter phase 2 study, an extended 7-day regimen with oral aprepitant (125 mg oral day 1, 80 mg oral days 2–7) combined with a 5-HT3 antagonist (days 1–5) and dexamethasone (8 mg oral days 1–8) was evaluated in patients with germ cell tumors undergoing anticancer therapy cycles with 5-day cisplatin-based regimens (N = 50).[246] During cycle 1 of anticancer therapy, 96% of patients had no emesis on day 1 and 82% had no emesis during days 1 to 7. In addition, 71% had no nausea on day 1 of cycle 1, and 27% had no nausea during days 1 to 7. More than 80% of patients had no emesis on any given day of any given anticancer therapy cycle. No unexpected or serious adverse events were reported.[246]

NK1 antagonists may be used for multiday anticancer therapy likely to be moderately or highly emetogenic and associated with significant risk for delayed nausea and emesis. As per the labeled indication, 125 mg of oral aprepitant should be administered 1 hour prior to anticancer therapy on day 1, along with a 5-HT3 antagonist and dexamethasone. Oral aprepitant 80 mg should be administered daily on days 2 and 3 after the start of anticancer therapy along with dexamethasone.[231] Repeated dosing of oral aprepitant over multiple cycles of cisplatin-based therapy appears to be feasible and well tolerated; importantly, protection from emesis and from significant nausea was maintained during the subsequent cycles of emetogenic anticancer therapy.[231,245] Based on smaller studies, oral aprepitant 80 mg may be safely administered beyond day 3 of initiating anticancer therapy.[132,246] Alternatively, for HEC regimens, aprepitant

injectable emulsion 130 mg intravenous or fosaprepitant 150 mg intravenous with dexamethasone may be given on day 1, with no need for oral aprepitant on days 2 and 3, with recommended dosing of dexamethasone on days 2 to 4. Data are not available for repeat dosing of fosaprepitant, aprepitant injectable emulsion, NEPA, or oral rolapitant.

Summary

The NCCN Guidelines for Antiemesis provide an overview of the principles for preventing or substantially decreasing anticancer agent–induced or RT-induced nausea and/or vomiting, and provide recommendations for prophylactic antiemetic regimens based on the emetogenic potential of anticancer agents. Prophylactic antiemetic regimens are recommended for patients who will receive emetogenic anticancer agents, because it is harder to control nausea and/or vomiting once it has started. Although vomiting can often be prevented or substantially decreased by using prophylactic antiemetic regimens, nausea is harder to control. The updates for 2020 are outlined in the *Summary of the Guidelines Updates* (see the NCCN Guidelines for Antiemesis). This Discussion text for antiemesis describes the recent updates in greater detail, for example, by including the clinical trial data and references that support the NCCN Panel's recommendations in the algorithm.

For the 2020 update, the NCCN Panel voted that the 4-drug olanzapine regimen—olanzapine, NK1 RA, 5-HT3 RA, dexamethasone—is the preferred regimen for patients at high risk for emesis from parenteral anticancer agents. In addition, NCCN Panel classified the emetogenic potential of 14 new anticancer agents and reclassified some older agents for the 2020 update. Enfortumab vedotin-ejfv and fam-trastuzumab deruxtecan-nxki are parenteral anticancer agents that are classified as moderate emetic risk. Mogamulizumab, moxetumomab, polatuzumab vedotin, and tagraxofusp are parenteral anticancer agents that are classified as low emetic risk; arsenic trioxide was reclassified as low emetic risk. Cemiplimab and trastuzumab/hyaluronidase are parenteral anticancer agents that are classified as minimal emetic risk. Avapritinib and selinexor are oral anticancer agents that are classified as moderate to high emetic risk; binimetinib and encorafenib were reclassified as moderate to high emetic risk. Alpelisib, entrectinib, erdafitinib, and zanubrutinib are oral anticancer agents that are classified as minimal to low emetic risk; trifluridine/tipiracil was reclassified as minimal to low emetic risk.

Certain patients who will be receiving MEC are at greater risk for emesis, because they have additional risk factors. The NCCN Panel clarified these risk factors for anticancer agent–inducing emesis; they include younger age; female sex; anxiety and/or high pretreatment expectation of nausea and/or vomiting; and history of CINV, motion sickness, morning sickness during pregnancy, and little or no alcohol use. Therefore, clinicians should consider using 3-drug antiemetic regimens for MEC for these patients.

For the 2020 update, the NCCN Panel added caveats about drug-drug interactions after extensive discussions. Short-term use of antiemetics may not result in clinically relevant drug interactions with anticancer agents; no clinically significant drug-drug interactions occurred in the randomized trials of anticancer agents with antiemetics.[53] The NCCN Panel also revised previous statements about the potential risk for drug-drug interactions for the 2020 update. The panel deleted previous precautions about using immune checkpoint inhibitor monotherapy with corticosteroid antiemetic regimens. However, corticosteroid antiemetics should be avoided for 3 to 5 days before and 90 days after CAR T-cell therapies. Replacing dexamethasone with olanzapine is an option for patients who cannot tolerate or take steroids. The panel also deleted recommendations for ECG monitoring in patients taking antiemetics such as olanzapine, benzodiazepines, or haloperidol.

References

1. Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 2016;374:1356-1367. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27050207.

2. McDonagh M, Peterson K, Thakurta S. Consideration of evidence on antiemetic drugs for nausea and vomiting associated with chemotherapy or radiation therapy in adults. Rockville (MD): Agency for Healthcare Research and Quality (US); 2010 Jul.

3. Laszlo J. Emesis as limiting toxicity in cancer chemotherapy. In: Laszlo J, ed. Antiemetics and Cancer Chemotherapy. Baltimore, Maryland: Williams & Wilkins; 1983:1-5.

4. Ingle RJ, Burish TG, Wallston KA. Conditionability of cancer chemotherapy patients. Oncol Nurs Forum 1984;11:97-102. Available at: https://www.ncbi.nlm.nih.gov/pubmed/6566342.

5. Mitchell EP. Gastrointestinal toxicity of chemotherapeutic agents. Semin Oncol 1992;19:566-579. Available at: https://www.ncbi.nlm.nih.gov/pubmed/1411654.

6. Richardson JL, Marks G, Levine A. The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol 1988;6:1746-1752. Available at: https://www.ncbi.nlm.nih.gov/pubmed/3183704.

7. Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 2008;5:32-43. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18097455.

8. Hesketh PJ, Grunberg SM, Herrstedt J, et al. Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 2006;14:354-360. Available at: https://www.ncbi.nlm.nih.gov/pubmed/16450086.

9. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-109. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8996130.

10. Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010;21 Suppl 5:v232-243. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20555089.

11. Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004;100:2261-2268. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15139073.

12. Ng TL, Hutton B, Clemons M. Chemotherapy-induced nausea and vomiting: Time for more emphasis on nausea? Oncologist 2015;20:576-583. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25948677.

13. Boccia RV, Gordan LN, Clark G, et al. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer 2011;19(10):1609-1617. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20835873.

14. Roscoe JA, Morrow GR, Colagiuri B, et al. Insight in the prediction of chemotherapy-induced nausea. Support Care Cancer 2010;18:869-876. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19701781.

15. NCCN antiemesis practice guidelines. Oncology (Williston Park) 1997;11:57-89. Available at: https://www.ncbi.nlm.nih.gov/pubmed/9430179.

16. Chan A, Abdullah MM, Ishak W, et al. Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of

Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement. J Glob Oncol 2017;3:801-813. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29244998.

17. American Gastroenterological A. American Gastroenterological Association medical position statement: nausea and vomiting. Gastroenterology 2001;120:261-263. Available at: https://www.ncbi.nlm.nih.gov/pubmed/11208735.

18. Craig JB, Powell BL. The management of nausea and vomiting in clinical oncology. Am J Med Sci 1987;293:34-44. Available at: https://www.ncbi.nlm.nih.gov/pubmed/3544842.

19. Borison HL, Wang SC. Physiology and pharmacology of vomiting. Pharmacol Rev 1953;5:193-230. Available at: https://www.ncbi.nlm.nih.gov/pubmed/13064033.

20. Seigel LJ, Longo DL. The control of chemotherapy-induced emesis. Ann Intern Med 1981;95:352-359. Available at: https://www.ncbi.nlm.nih.gov/pubmed/7023313.

21. Dodds LJ. The control of cancer chemotherapy-induced nausea and vomiting. J Clin Hosp Pharm 1985;10:143-166. Available at: https://www.ncbi.nlm.nih.gov/pubmed/2862166.

22. Chow R, Chiu L, Navari R, et al. Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review. Support Care Cancer 2016;24:1001-1008. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26530228.

23. Morrow GR, Navari RM, Rugo HS. Clinical roundtable monograph: New data in emerging treatment options for chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol 2014;12:1-14; quiz 15. Available at: https://www.ncbi.nlm.nih.gov/pubmed/24874107.

24. Boccia RV, Gordan LN, Clark G, et al. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer 2011;19:1609-1617. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20835873.

25. Aapro MS. Palonosetron as an anti-emetic and anti-nausea agent in oncology. Ther Clin Risk Manag 2007;3:1009-1020. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18516316.

26. Hickok JT, Roscoe JA, Morrow GR, et al. 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol 2005;6:765-772. Available at: https://www.ncbi.nlm.nih.gov/pubmed/16198982.

27. Singh P, Yoon SS, Kuo B. Nausea: a review of pathophysiology and therapeutics. Therap Adv Gastroenterol 2016;9:98-112. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26770271.

28. Quigley EM, Hasler WL, Parkman HP. AGA technical review on nausea and vomiting. Gastroenterology 2001;120:263-286. Available at: https://www.ncbi.nlm.nih.gov/pubmed/11208736.

29. Warr DG, Street JC, Carides AD. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Support Care Cancer 2011;19:807-813. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20461438.

30. Kris MG, Gralla RJ, Clark RA, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985;3:1379-1384. Available at: https://www.ncbi.nlm.nih.gov/pubmed/4045527.

31. Roila F, Boschetti E, Tonato M, et al. Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Am J Clin Oncol 1991;14:238-242. Available at: https://www.ncbi.nlm.nih.gov/pubmed/2031511.

32. Moher D, Arthur AZ, Pater JL. Anticipatory nausea and/or vomiting. Cancer Treat Rev 1984;11:257-264. Available at: https://www.ncbi.nlm.nih.gov/pubmed/6151870.

33. Jacobsen PB, Redd WH. The development and management of chemotherapy-related anticipatory nausea and vomiting. Cancer Invest 1988;6:329-336. Available at: https://www.ncbi.nlm.nih.gov/pubmed/3048577.

34. Morrow GR. Clinical characteristics associated with the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment. J Clin Oncol 1984;2:1170-1176. Available at: https://www.ncbi.nlm.nih.gov/pubmed/6491699.

35. Roila F, Hesketh PJ, Herrstedt J, Antiemetic Subcommitte of the Multinational Association of Supportive Care in C. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006;17:20-28. Available at: https://www.ncbi.nlm.nih.gov/pubmed/16314401.

36. Navari RM. Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents. Drugs 2013;73:249-262. Available at: https://www.ncbi.nlm.nih.gov/pubmed/23404093.

37. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2017;35:3240-3261. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28759346.

38. Feyer PC, Maranzano E, Molassiotis A, et al. Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009. Support Care Cancer 2011;19 Suppl 1:S5-14. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20697746.

39. Harding R, Young R, Anno G. Radiotherapy-induced emesis. In: Andrews P, Sanger G, eds. Emesis in Anti-Cancer Therapy. London: Chapman & Hall Medical; 1993:163-178.

40. Clemmons AB, Orr J, Andrick B, et al. Randomized, placebo-controlled, phase III trial of fosaprepitant, ondansetron, dexamethasone (FOND) versus FOND plus olanzapine (FOND-O) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens: The FOND-O Trial. Biol Blood Marrow Transplant 2018;24:2065-2071. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29906570.

41. American Society of Clinical O, Kris MG, Hesketh PJ, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932-2947. Available at: https://www.ncbi.nlm.nih.gov/pubmed/16717289.

42. Laszlo J. Treatment of nausea and vomiting caused by cancer chemotherapy. Cancer Treat Rev 1982;9 Suppl B:3-9. Available at: https://www.ncbi.nlm.nih.gov/pubmed/6299552.

43. Strum SB, McDermed JE, Pileggi J, et al. Intravenous metoclopramide: prevention of chemotherapy-induced nausea and vomiting. A preliminary evaluation. Cancer 1984;53:1432-1439. Available at: https://www.ncbi.nlm.nih.gov/pubmed/6692333.

44. Lindley CM, Bernard S, Fields SM. Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J Clin Oncol 1989;7:1142-1149. Available at: https://www.ncbi.nlm.nih.gov/pubmed/2787840.

45. Aapro M. Methodological issues in antiemetic studies. Invest New Drugs 1993;11:243-253. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8157467.

46. Grunberg SM, Warr D, Gralla RJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art. Support Care Cancer 2011;19 Suppl 1:S43-47. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20972805.

47. Okuyama A, Nakamura F, Higashi T. Prescription of prophylactic antiemetic drugs for patients receiving chemotherapy with minimal and low

emetic risk. JAMA Oncol 2017;3:344-350. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27812688.

48. Encinosa W, Davidoff AJ. Changes in antiemetic overuse in response to Choosing Wisely recommendations. JAMA Oncol 2017;3:320-326. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27632203.

49. Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009;27:504-510. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19075265.

50. Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2018;19:603-615. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29573941.

51. Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015;372:1909-1919. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25970050.

52. Miller EM, Schwartzberg LS. Biosimilars for breast cancer: a review of HER2-targeted antibodies in the United States. Ther Adv Med Oncol 2019;11:1758835919887044. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31798693.

53. Herrstedt J, Dombernowsky P. Anti-emetic therapy in cancer chemotherapy: current status. Basic Clin Pharmacol Toxicol 2007;101:143-150. Available at: https://www.ncbi.nlm.nih.gov/pubmed/17697032.

54. Hesketh PJ, Gandara DR. Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 1991;83:613-620. Available at: https://www.ncbi.nlm.nih.gov/pubmed/1850806.

55. Andrews PL, Bhandari P, Davey PT, et al. Are all 5-HT3 receptor antagonists the same? Eur J Cancer 1992;28A Suppl 1:2-6. Available at: https://www.ncbi.nlm.nih.gov/pubmed/1320915.

56. Grunberg SM, Koeller JM. Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis. Expert Opin Pharmacother 2003;4:2297-2303. Available at: https://www.ncbi.nlm.nih.gov/pubmed/14640928.

57. Grunberg SM, Stevenson LL, Russell CA, McDermed JE. Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1989;7:1137-1141. Available at: https://www.ncbi.nlm.nih.gov/pubmed/2526864.

58. Chevallier B. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group. Eur J Cancer 1990;26 Suppl 1:S33-36. Available at: https://www.ncbi.nlm.nih.gov/pubmed/2169784.

59. Cupissol DR, Serrou B, Caubel M. The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis. Eur J Cancer 1990;26 Suppl 1:23-27. Available at: https://www.ncbi.nlm.nih.gov/pubmed/2169782.

60. De Mulder PH, Seynaeve C, Vermorken JB, et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. Ann Intern Med 1990;113:834-840. Available at: https://www.ncbi.nlm.nih.gov/pubmed/2146911.

61. Marty M. A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. The Granisetron Study Group. Eur J Cancer 1990;26 Suppl 1:S28-32. Available at: https://www.ncbi.nlm.nih.gov/pubmed/2169783.

62. Marty M, Pouillart P, Scholl S, et al. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990;322:816-821. Available at: https://www.ncbi.nlm.nih.gov/pubmed/2137902.

63. Soukop M. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group. Eur J Cancer 1990;26 Suppl 1:S15-19. Available at: https://www.ncbi.nlm.nih.gov/pubmed/2169779.

64. Roila F, Tonato M, Cognetti F, et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991;9:675-678. Available at: https://www.ncbi.nlm.nih.gov/pubmed/1829757.

65. Fraschini G. Antiemetic activity of ondansetron in cancer patients receiving non-cisplatin chemotherapy. Semin Oncol 1992;19:41-47. Available at: https://www.ncbi.nlm.nih.gov/pubmed/1387249.

66. Kamanabrou D. Intravenous granisetron--establishing the optimal dose. The Granisetron Study Group. Eur J Cancer 1992;28A Suppl 1:6-11. Available at: https://www.ncbi.nlm.nih.gov/pubmed/1320919.

67. Sledge GW, Einhorn L, Nagy C, House K. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer 1992;70:2524-2528. Available at: https://www.ncbi.nlm.nih.gov/pubmed/1423181.

68. Chevallier B. The control of acute cisplatin-induced emesis--a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. Granisetron Study Group. Br J Cancer 1993;68:176-180. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8391304.

69. Navari RM, Kaplan HG, Gralla RJ, et al. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 1994;12:2204-2210. Available at: https://www.ncbi.nlm.nih.gov/pubmed/7931490.

70. Riviere A. Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. The Granisetron Study Group. Br J Cancer 1994;69:967-971. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8180032.

71. Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17:1441-1449. Available at: https://www.ncbi.nlm.nih.gov/pubmed/16766588.

72. Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009;10:115-124. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19135415.

73. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003;98:2473-2482. Available at: https://www.ncbi.nlm.nih.gov/pubmed/14635083.

74. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570-1577. Available at: https://www.ncbi.nlm.nih.gov/pubmed/14504060.

75. Bonneterre J, Hecquet B. Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately-emetogenic chemotherapy. A cross-over study. Bull Cancer

1995;82:1038-1043. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8745670.

76. Jantunen IT, Muhonen TT, Kataja VV, et al. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy--a randomised study. Eur J Cancer 1993;29A:1669-1672. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8398291.

77. Martoni A, Angelelli B, Guaraldi M, et al. An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens. Eur J Cancer 1996;32A:82-85. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8695248.

78. Gebbia V, Cannata G, Testa A, et al. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. Cancer 1994;74:1945-1952. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8082100.

79. Mantovani G, Maccio A, Bianchi A, et al. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. Cancer 1996;77:941-948. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8608488.

80. Noble A, Bremer K, Goedhals L, et al. A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. The Granisetron Study Group. Eur J Cancer 1994;30A:1083-1088. Available at: https://www.ncbi.nlm.nih.gov/pubmed/7654434.

81. Ruff P, Paska W, Goedhals L, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group. Oncology 1994;51:113-118. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8265095.

82. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group of Antiemetic Research. Ann Oncol 1995;6:805-810. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8589019.

83. Navari R, Gandara D, Hesketh P, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. J Clin Oncol 1995;13:1242-1248. Available at: https://www.ncbi.nlm.nih.gov/pubmed/7738628.

84. Stewart A, McQuade B, Cronje JD, et al. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Emesis Study Group for Ondansetron and Granisetron in Breast Cancer Patients. Oncology 1995;52:202-210. Available at: https://www.ncbi.nlm.nih.gov/pubmed/7715904.

85. Audhuy B, Cappelaere P, Martin M, et al. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 1996;32A:807-813. Available at: https://www.ncbi.nlm.nih.gov/pubmed/9081358.

86. Fauser AA, Duclos B, Chemaissani A, et al. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group. Eur J Cancer 1996;32A:1523-1529. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8911112.

87. Hesketh P, Navari R, Grote T, et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. J Clin Oncol 1996;14:2242-2249. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8708713.

88. Lofters WS, Pater JL, Zee B, et al. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 1997;15:2966-2973. Available at: https://www.ncbi.nlm.nih.gov/pubmed/9256141.

89. Jordan K, Hinke A, Grothey A, et al. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer 2007;15:1023-1033. Available at: https://www.ncbi.nlm.nih.gov/pubmed/17205281.

90. Billio A, Morello E, Clarke MJ. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults. Cochrane Database Syst Rev 2010:CD006272. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20091591.

91. Botrel TE, Clark OA, Clark L, et al. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer 2011;19:823-832. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20495832.

92. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011;29:4189-4198. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21947834.

93. Raftopoulos H, Cooper W, O'Boyle E, et al. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial. Support Care Cancer 2015;23:723-732. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25179689.

94. Huang JQ, Zheng GF, Deuson R, et al. Do 5-hydroxytryptamine3 receptor antagonists (5-HT3) improve the antiemetic effect of dexamethasone for preventing delayed chemotherapy-induced nausea and vomiting (CINV)? A meta-analysis of randomized controlled trials [abstract]. J Clin Oncol 2004;22(Suppl 14): Abstract 6037. Available at: https://meeting.ascopubs.org/cgi/content/abstract/22/14_suppl/6037.

95. Grote T, Hajdenberg J, Cartmell A, et al. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol 2006;4:403-408. Available at: https://www.ncbi.nlm.nih.gov/pubmed/17004515.

96. Grunberg SM, Dugan M, Muss H, et al. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer 2009;17:589-594. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19037667.

97. Longo F, Mansueto G, Lapadula V, et al. Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 2011;19:1159-1164. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20552375.

98. Miura S, Watanabe S, Sato K, et al. The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy. Support Care Cancer 2013;21:2575-2581. Available at: https://www.ncbi.nlm.nih.gov/pubmed/23644992.

99. Schwartzberg LS, Gabrail NY, Hrom JS, et al. Phase III MAGIC trial of APF530 v ondansetron (Ond) with fosaprepitant (Fos) + dexamethasone (Dex) for highly emetogenic chemotherapy (HEC)-induced nausea and vomiting: analysis by age and gender [abstract]. J Clin Oncol 2017;34:e21700. Available at: https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.e21700.

100. Schnadig ID, Agajanian R, Dakhil C, et al. APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in

highly emetogenic chemotherapy. Future Oncol 2016;12:1469-1481. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26997579.

101. Doggrell SA, Hancox JC. Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia. Expert Opin Drug Saf 2013;12:421-431. Available at: https://www.ncbi.nlm.nih.gov/pubmed/23578248.

102. United States Food and Drug Administration. FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran). 2012. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm310190.htm. Accessed

103. Brygger L, Herrstedt J, Academy of Geriatric Cancer R. 5-Hydroxytryptamine3 receptor antagonists and cardiac side effects. Expert Opin Drug Saf 2014;13:1407-1422. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25196083.

104. FDA Drug Safety Communication: Abnormal heart rhythms associated with use of Anzemet (dolasetron mesylate). Available at: https://www.fda.gov/Drugs/DrugSafety/ucm237081.htm.

105. Howell J, Smeets J, Drenth HJ, Gill D. Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting. J Oncol Pharm Pract 2009;15:223-231. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19304880.

106. Seol YM, Kim HJ, Choi YJ, et al. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study. Support Care Cancer 2016;24:945-952. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26265119.

107. Aapro M, Fabi A, Nole F, et al. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 2010;21:1083-1088. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20080830.

108. Charbit B, Albaladejo P, Funck-Brentano C, et al. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology 2005;102:1094-1100. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15915019.

109. Tricco AC, Soobiah C, Blondal E, et al. Comparative safety of serotonin (5-HT3) receptor antagonists in patients undergoing surgery: a systematic review and network meta-analysis. BMC Med 2015;13:142. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26084332.

110. Hendren G, Aponte-Feliciano A, Kovac A. Safety and efficacy of commonly used antiemetics. Expert Opin Drug Metab Toxicol 2015;11:1753-1767. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26293198.

111. Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Ann Emerg Med 2014;64:19-25 e16. Available at: https://www.ncbi.nlm.nih.gov/pubmed/24314899.

112. FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran). Available at: https://www.fda.gov/Drugs/DrugSafety/ucm271913.htm.

113. Baltzer L, Kris MG, Hinkley L, et al. Reversible electrocardiographic interval prolongations following the specific serotonin antagonists ondanestron (OND) and dolasetron mesylate (DM): a possible drug class effect without sequelae? [abstract]. J Clin Oncol 1994;13:Abstract 1489.

114. Gonullu G, Demircan S, Demirag MK, et al. Electrocardiographic findings of palonosetron in cancer patients. Support Care Cancer 2012;20:1435-1439. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21773677.

115. Leonard MC, Militello ML. 5-HT3 Receptor antagonists and ECG effects. Pharmacotherapy Updates; 2002. Available at:

https://www.clevelandclinicmeded.com/medicalpubs/pharmacy/novdec2002/5ht.htm.

116. Hafermann MJ, Namdar R, Seibold GE, Page RL, 2nd. Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study. Drug Healthc Patient Saf 2011;3:53-58. Available at: https://www.ncbi.nlm.nih.gov/pubmed/22046106.

117. Rojas C, Li Y, Zhang J, et al. The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther 2010;335:362-368. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20724484.

118. Rojas C, Thomas AG, Alt J, et al. Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 2010;626:193-199. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19836386.

119. Chow R, Warr DG, Navari RM, et al. Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis. Support Care Cancer 2018;26:2519-2549. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29796708.

120. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003;98:2473-2482. Available at: https://www.ncbi.nlm.nih.gov/pubmed/14635083.

121. Giralt SA, Mangan KF, Maziarz RT, et al. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Ann Oncol 2011;22:939-946. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20935058.

122. Gregory RE, Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs 1998;55:173-189. Available at: https://www.ncbi.nlm.nih.gov/pubmed/9506240.

123. Gralla RJ, de Wit R, Herrstedt J, et al. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials. Cancer 2005;104:864-868. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15973669.

124. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21:4112-4119. Available at: https://www.ncbi.nlm.nih.gov/pubmed/14559886.

125. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97:3090-3098. Available at: https://www.ncbi.nlm.nih.gov/pubmed/12784346.

126. Ottoboni T, Keller MR, Cravets M, et al. Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation. Drug Des Devel Ther 2018;12:429-435. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29535504.

127. dos Santos LV, Souza FH, Brunetto AT, et al. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst 2012;104:1280-1292. Available at: https://www.ncbi.nlm.nih.gov/pubmed/22911671.

128. Tremont-Lukats IW, Gonzalez-Barboteo J, Bruera E, Brescia FJ. Meta-analysis of neurokinin-1 receptor antagonists (NK-1 RA) for

chemotherapy-induced nausea and vomiting (CINV) [abstract]. J Clin Oncol 2004;22(Suppl 14):Abstract 8047. Available at: https://meeting.ascopubs.org/cgi/content/abstract/22/14_suppl/8047.

129. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-2830. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15837996.

130. Schmitt T, Goldschmidt H, Neben K, et al. Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial. J Clin Oncol 2014;32:3413-3420. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25225424.

131. Rapoport BL, Jordan K, Boice JA, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 2010;18:423-431. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19568773.

132. Chawla SP, Grunberg SM, Gralla RJ, et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003;97:2290-2300. Available at: https://www.ncbi.nlm.nih.gov/pubmed/12712486.

133. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97:3090-3098. Available at: https://www.ncbi.nlm.nih.gov/pubmed/12784346.

134. Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. J Clin Oncol 2011;29:1495-1501. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21383291.

135. Marbury TC, Ngo PL, Shadle CR, et al. Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects. J Clin Pharmacol 2011;51:1712-1720. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21209230.

136. Lasseter KC, Gambale J, Jin B, et al. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol 2007;47:834-840. Available at: https://www.ncbi.nlm.nih.gov/pubmed/17525168.

137. Chau E, Lundberg J, Phillips G, et al. Updated report on incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant. J Oncol Pharm Pract 2019;25:1053-1057. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29651918.

138. Leal AD, Kadakia KC, Looker S, et al. Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy. Support Care Cancer 2014;22:1313-1317. Available at: https://www.ncbi.nlm.nih.gov/pubmed/24402411.

139. Shadle CR, Lee Y, Majumdar AK, et al. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 2004;44:215-223. Available at: https://www.ncbi.nlm.nih.gov/pubmed/14973304.

140. Patel P, Leeder JS, Piquette-Miller M, Dupuis LL. Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol 2017;83:2148-2162. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28470980.

141. Hesketh PJ, Rossi G, Rizzi G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol

2014;25:1340-1346. Available at: https://www.ncbi.nlm.nih.gov/pubmed/24608196.

142. Hesketh PJ, Bohlke K, Lyman GH, et al. Antiemetics: American Society of Clinical Oncology Focused Guideline Update. J Clin Oncol 2016;34:381-386. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26527784.

143. Aapro M, Rugo H, Rossi G, et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 2014;25:1328-1333. Available at: https://www.ncbi.nlm.nih.gov/pubmed/24603643.

144. Schwartzberg LS, Rugo HS, Aapro MS. New and emerging therapeutic options for the management of chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol 2015;13:3-13, 11; quiz 12 p following 14. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25856052.

145. Zhang L, Lu S, Feng J, et al. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Ann Oncol 2018;29:452-458. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29092012.

146. Schwartzberg L, Roeland E, Andric Z, et al. Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy. Ann Oncol 2018;29:1535-1540. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29722791.

147. Schwartzberg LS, Modiano MR, Rapoport BL, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol 2015;16:1071-1078. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26272768.

148. Rapoport BL, Chasen MR, Gridelli C, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol 2015;16:1079-1089. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26272769.

149. Wampler G. The pharmacology and clinical effectiveness of phenothiazines and related drugs for managing chemotherapy-induced emesis. Drugs 1983;25 Suppl 1:35-51. Available at: https://www.ncbi.nlm.nih.gov/pubmed/6840019.

150. Gralla RJ, Itri LM, Pisko SE, et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981;305:905-909. Available at: https://www.ncbi.nlm.nih.gov/pubmed/7024807.

151. Gralla RJ, Tyson LB, Bordin LA, et al. Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol. Cancer Treat Rep 1984;68:163-172. Available at: https://www.ncbi.nlm.nih.gov/pubmed/6318993.

152. Bakowski MT. Advances in anti-emetic therapy. Cancer Treat Rev 1984;11:237-256. Available at: https://www.ncbi.nlm.nih.gov/pubmed/6098368.

153. Grossman B, Lessin LS, Cohen P. Droperidol prevents nausea and vomiting from cis-platinum. N Engl J Med 1979;301:47. Available at: https://www.ncbi.nlm.nih.gov/pubmed/449910.

154. Aapro MS, Alberts DS. High-dose dexamethasone for prevention of cis-platin-induced vomiting. Cancer Chemother Pharmacol 1981;7:11-14. Available at: https://www.ncbi.nlm.nih.gov/pubmed/6122510.

155. Aapro MS, Plezia PM, Alberts DS, et al. Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide. J Clin Oncol 1984;2:466-471. Available at: https://www.ncbi.nlm.nih.gov/pubmed/6539363.

156. Cassileth PA, Lusk EJ, Torri S, et al. Antiemetic efficacy of dexamethasone therapy in patients receiving cancer chemotherapy. Arch Intern Med 1983;143:1347-1349. Available at: https://www.ncbi.nlm.nih.gov/pubmed/6347109.

157. Kris MG, Gralla RJ, Clark RA, et al. Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone. Cancer Treat Rep 1985;69:1257-1262. Available at: https://www.ncbi.nlm.nih.gov/pubmed/3912039.

158. Kris MG, Gralla RJ, Clark RA, et al. Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial. Cancer 1987;60:2816-2822. Available at: https://www.ncbi.nlm.nih.gov/pubmed/3315176.

159. Herman TS, Einhorn LH, Jones SE, et al. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 1979;300:1295-1297. Available at: https://www.ncbi.nlm.nih.gov/pubmed/375088.

160. Steele N, Gralla RJ, Braun DW, Jr., Young CW. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat Rep 1980;64:219-224. Available at: https://www.ncbi.nlm.nih.gov/pubmed/6250699.

161. Chu CC, Hsing CH, Shieh JP, et al. The cellular mechanisms of the antiemetic action of dexamethasone and related glucocorticoids against vomiting. Eur J Pharmacol 2014;722:48-54. Available at: https://www.ncbi.nlm.nih.gov/pubmed/24184695.

162. Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol 2000;18:3409-3422. Available at: https://www.ncbi.nlm.nih.gov/pubmed/11013282.

163. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research. J Clin Oncol 1998;16:2937-2942. Available at: https://www.ncbi.nlm.nih.gov/pubmed/9738561.

164. Italian Group For Antiemetic R. Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. J Clin Oncol 2004;22:725-729. Available at: https://www.ncbi.nlm.nih.gov/pubmed/14966097.

165. Ito Y, Tsuda T, Minatogawa H, et al. Placebo-controlled, double-blinded phase III study comparing dexamethasone on Day 1 with dexamethasone on Days 1 to 3 with combined neurokinin-1 receptor antagonist and palonosetron in high-emetogenic chemotherapy. J Clin Oncol 2018;36:1000-1006. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29443652.

166. Okada Y, Oba K, Furukawa N, et al. One-day versus three-day dexamethasone in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and individual patient data-based meta-analysis. Oncologist 2019;24:1593-1600. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31217343.

167. Celio L, Bonizzoni E, Zattarin E, et al. Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence. BMC Cancer 2019;19:1268. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31888544.

168. Matsuzaki K, Ito Y, Fukuda M, et al. Placebo-controlled phase III study comparing dexamethasone on day 1 to on day 1-3 with NK1 receptor antagonist and palonosetoron in high emetogenic chemotherapy

[abstract]. J Clin Oncol 2016;34:Abstract 10019. Available at: https://meetinglibrary.asco.org/print/2405886.

169. Celio L, Bonizzoni E, Bajetta E, et al. Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials. Support Care Cancer 2013;21:565-573. Available at: https://www.ncbi.nlm.nih.gov/pubmed/22869054.

170. Roila F, Ruggeri B, Ballatori E, et al. Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study. J Clin Oncol 2014;32:101-106. Available at: https://www.ncbi.nlm.nih.gov/pubmed/24323030.

171. Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double-blind, placebo-controlled trial [abstract]. J Clin Oncol 2015;33:Abstract 176. Available at: https://meetinglibrary.asco.org/content/155048-165.

172. Navari RM, Einhorn LH, Passik SD, et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 2005;13:529-534. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15700131.

173. Srivastava M, Brito-Dellan N, Davis MP, et al. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manage 2003;25:578-582. Available at: https://www.ncbi.nlm.nih.gov/pubmed/12782438.

174. Passik SD, Navari RM, Jung SH, et al. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest 2004;22:383-388. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15493359.

175. Passik SD, Kirsh KL, Theobald DE, et al. A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manage 2003;25:485-488. Available at: https://www.ncbi.nlm.nih.gov/pubmed/12727048.

176. Passik SD, Lundberg J, Kirsh KL, et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage 2002;23:526-532. Available at: https://www.ncbi.nlm.nih.gov/pubmed/12067777.

177. Navari RM, Einhorn LH, Loehrer PJ, Sr., et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer 2007;15:1285. Available at: https://www.ncbi.nlm.nih.gov/pubmed/17375339.

178. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 2011;9:188-195. Available at: https://www.ncbi.nlm.nih.gov/pubmed/22024310.

179. Tan L, Liu J, Liu X, et al. Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 2009;28:131. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19775450.

180. Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 2016;375:134-142. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27410922.

181. Sutherland A, Naessens K, Plugge E, et al. Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev 2018;9:CD012555. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30246876.

182. Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician 2010;81:617-622. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20187598.

183. Morita T, Tei Y, Shishido H, Inoue S. Olanzapine-induced delirium in a terminally ill cancer patient. J Pain Symptom Manage 2004;28:102-103. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15276190.

184. Nakashima K, Murakami H, Yokoyama K, et al. A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy. Jpn J Clin Oncol 2017;47:840-843. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28633504.

185. Zhou JG, Huang L, Jin SH, et al. Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. ESMO Open 2020;5. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32079622.

186. Yanai T, Iwasa S, Hashimoto H, et al. A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. Int J Clin Oncol 2018;23:382-388. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29039073.

187. Chiu L, Chow R, Popovic M, et al. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Support Care Cancer 2016;24:2381-2392. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26768437.

188. Hashimoto H, Yanai T, Nagashima K, et al. A double-blind randomized phase II study of 10 versus 5 mg olanzapine for emesis induced by highly emetogenic chemotherapy with cisplatin [abstract]. J Clin Oncol 2016;34:Abstract 10111. Available at: https://meetinglibrary.asco.org/content/162219-176.

189. Hoffmann MS, Overman MJ, Nates JL. Acute benzodiazepine toxicity exacerbated by concomitant oral olanzapine. J Community Support Oncol 2016;14:178-179. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27152518.

190. National Cancer Institute. Eating hints: before, during, and after cancer treatment. 2009. Available at: https://www.cancer.gov/cancertopics/coping/eatinghints/page1. Accessed

191. Jordan K, Gralla R, Rizzi G, Kashef K. Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens. Support Care Cancer 2016;24:4617-4625. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27334131.

192. Di Maio M, Baratelli C, Bironzo P, et al. Efficacy of neurokinin-1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based chemotherapy: A systematic review and meta-analysis. Crit Rev Oncol Hematol 2018;124:21-28. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29548482.

193. Jordan K, Blattermann L, Hinke A, et al. Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis. Support Care Cancer 2018;26:21-32. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28861627.

194. Weinstein C, Jordan K, Green SA, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. Ann Oncol 2016;27:172-178. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26449391.

195. Hesketh PJ, Schnadig ID, Schwartzberg LS, et al. Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy. Cancer 2016;122:2418-2425. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27176138.

196. Geling O, Eichler H-G. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 2005;23:1289-1294. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15718327.

197. United States Food and Drug Administration FDA News Release: FDA requires boxed warning and risk mitigation strategy for metoclopramide-containing drugs; Agency warns against chronic use of these products to treat gastrointestinal disorders. 2009. Available at: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/metoclopramide-information.

198. Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol 2006;3:138-148. Available at: https://www.ncbi.nlm.nih.gov/pubmed/16511548.

199. Kawanishi C, Onishi H, Kato D, et al. Unexpectedly high prevalence of akathisia in cancer patients. Palliat Support Care 2007;5:351-354. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18044412.

200. Patanwala AE, Amini R, Hays DP, Rosen P. Antiemetic therapy for nausea and vomiting in the emergency department. J Emerg Med 2010;39:330-336. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20022195.

201. Vinson DR. Diphenhydramine in the treatment of akathisia induced by prochlorperazine. J Emerg Med 2004;26:265-270. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15028322.

202. van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. BMJ 1999;319:623-626. Available at: https://www.ncbi.nlm.nih.gov/pubmed/10473482.

203. Duma SR, Fung VS. Drug-induced movement disorders. Aust Prescr 2019;42:56-61. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31048939.

204. Savitt D, Jankovic J. Tardive syndromes. J Neurol Sci 2018;389:35-42. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29506749.

205. Vijayakumar D, Jankovic J. Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia. Drugs 2016;76:779-787. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27091214.

206. Roila F, Warr D, Clark-Snow RA, et al. Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer 2005;13:104-108. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15549426.

207. Clark-Snow R, Affronti ML, Rittenberg CN. Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses. Support Care Cancer 2018;26:557-564. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28871358.

208. Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 2013;21:1655-1663. Available at: https://www.ncbi.nlm.nih.gov/pubmed/23314603.

209. Einhorn LH, Rapoport B, Navari RM, et al. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 2017;25:303-308. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27815710.

210. Parikh N, Kramer WG, Khurana V, et al. Bioavailability study of dronabinol oral solution versus dronabinol capsules in healthy volunteers. Clin Pharmacol 2016;8:155-162. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27785111.

211. Urba S. Radiation-induced nausea and vomiting. J Natl Compr Canc Netw 2007;5:60-65. Available at: https://www.ncbi.nlm.nih.gov/pubmed/17239327.

212. Maranzano E, Feyer P, Molassiotis A, et al. Evidence-based recommendations for the use of antiemetics in radiotherapy. Radiother Oncol 2005;76:227-233. Available at: https://www.ncbi.nlm.nih.gov/pubmed/16150504.

213. McKenzie E, Zaki P, Raman S, et al. Radiation-induced nausea and vomiting: a comparison between MASCC/ESMO, ASCO, and NCCN antiemetic guidelines. Support Care Cancer 2019;27:783-791. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30607675.

214. Ruhlmann CH, Jahn F, Jordan K, et al. 2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting. Support Care Cancer 2017;25:309-316. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27624464.

215. Salvo N, Doble B, Khan L, et al. Prophylaxis of radiation-induced nausea and vomiting using 5-hydroxytryptamine-3 serotonin receptor antagonists: a systematic review of randomized trials. Int J Radiat Oncol Biol Phys 2012;82:408-417. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21075553.

216. Franzen L, Nyman J, Hagberg H, et al. A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy. Ann Oncol 1996;7:587-592. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8879372.

217. National Cancer Institute of Canada Clinical Trials G, Wong RK, Paul N, et al. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). J Clin Oncol 2006;24:3458-3464. Available at: https://www.ncbi.nlm.nih.gov/pubmed/16849762.

218. Lanciano R, Sherman DM, Michalski J, et al. The efficacy and safety of once-daily Kytril (granisetron hydrochloride) tablets in the prophylaxis of nausea and emesis following fractionated upper abdominal radiotherapy. Cancer Invest 2001;19:763-772. Available at: https://www.ncbi.nlm.nih.gov/pubmed/11768028.

219. Spitzer TR, Friedman CJ, Bushnell W, et al. Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation. Bone Marrow Transplant 2000;26:203-210. Available at: https://www.ncbi.nlm.nih.gov/pubmed/10918432.

220. Kamen C, Tejani MA, Chandwani K, et al. Anticipatory nausea and vomiting due to chemotherapy. Eur J Pharmacol 2014;722:172-179. Available at: https://www.ncbi.nlm.nih.gov/pubmed/24157982.

221. Roscoe JA, Morrow GR, Aapro MS, et al. Anticipatory nausea and vomiting. Support Care Cancer 2011;19:1533-1538. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20803345.

222. Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support Care Cancer 2005;13:117-121. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15599779.

223. Ezzo J, Vickers A, Richardson MA, et al. Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting. J Clin Oncol 2005;23:7188-7198. Available at: https://www.ncbi.nlm.nih.gov/pubmed/16192603.

224. Morrow GR, Morrell C. Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med 1982;307:1476-1480. Available at: https://www.ncbi.nlm.nih.gov/pubmed/6128673.

225. Redd WH, Andrykowski MA. Behavioral intervention in cancer treatment: controlling aversion reactions to chemotherapy. J Consult Clin Psychol 1982;50:1018-1029. Available at: https://www.ncbi.nlm.nih.gov/pubmed/7174969.

226. Ezzo J, Streitberger K, Schneider A. Cochrane systematic reviews examine P6 acupuncture-point stimulation for nausea and vomiting. J Altern Complement Med 2006;12:489-495. Available at: https://www.ncbi.nlm.nih.gov/pubmed/16813514.

227. Figueroa-Moseley C, Jean-Pierre P, Roscoe JA, et al. Behavioral interventions in treating anticipatory nausea and vomiting. J Natl Compr Canc Netw 2007;5:44-50. Available at: https://www.ncbi.nlm.nih.gov/pubmed/17239325.

228. Molassiotis A, Yung HP, Yam BM, et al. The effectiveness of progressive muscle relaxation training in managing chemotherapy-induced nausea and vomiting in Chinese breast cancer patients: a randomised controlled trial. Support Care Cancer 2002;10:237-246. Available at: https://www.ncbi.nlm.nih.gov/pubmed/11904789.

229. Razavi D, Delvaux N, Farvacques C, et al. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. J Clin Oncol 1993;11:1384-1390. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8315437.

230. Malik IA, Khan WA, Qazilbash M, et al. Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol 1995;18:170-175. Available at: https://www.ncbi.nlm.nih.gov/pubmed/7900711.

231. de Wit R, Herrstedt J, Rapoport B, et al. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer 2004;40:403-410. Available at: https://www.ncbi.nlm.nih.gov/pubmed/14746859.

232. Ellebaek E, Herrstedt J. Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy. Curr Opin Support Palliat Care 2008;2:28-34. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18685391.

233. Einhorn LH, Rapoport B, Koeller J, et al. Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 2005;13:112-116. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15480812.

234. Navari RM. Prevention of emesis from multiple-day and high-dose chemotherapy regimens. J Natl Compr Canc Netw 2007;5:51-59. Available at: https://www.ncbi.nlm.nih.gov/pubmed/17239326.

235. Herrstedt J, Sigsgaard TC, Nielsen HA, et al. Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy. Support Care Cancer 2007;15:417-426. Available at: https://www.ncbi.nlm.nih.gov/pubmed/17093916.

236. Jordan K, Warr DG, Hinke A, et al. Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings-a meta-analysis. Support Care Cancer 2016;24:1941-1954. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26476625.

237. Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics 2016;3:16011. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27626062.

238. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014;6:224ra225. Available at: https://www.ncbi.nlm.nih.gov/pubmed/24553386.

239. Mier JW, Vachino G, Klempner MS, et al. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood 1990;76:1933-1940. Available at: https://www.ncbi.nlm.nih.gov/pubmed/2242421.

240. Musso M, Scalone R, Bonanno V, et al. Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. Support Care

Cancer 2009;17:205-209. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18839220.

241. Celio L, Denaro A, Canova S, et al. Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting. Tumori 2008;94:447-452. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18822676.

242. Eisenberg P, MacKintosh FR, Ritch P, et al. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol 2004;15:330-337. Available at: https://www.ncbi.nlm.nih.gov/pubmed/14760130.

243. Einhorn LH, Brames MJ, Dreicer R, et al. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 2007;15:1293-1300. Available at: https://www.ncbi.nlm.nih.gov/pubmed/17436025.

244. Affronti ML, Bubalo J. Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy. Cancer Manag Res 2014;6:329-337. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25228819.

245. Albany C, Brames MJ, Fausel C, et al. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study. J Clin Oncol 2012;30:3998-4003. Available at: https://www.ncbi.nlm.nih.gov/pubmed/22915652.

246. Olver IN, Grimison P, Chatfield M, et al. Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy. Support Care Cancer 2013;21:1561-1568. Available at: https://www.ncbi.nlm.nih.gov/pubmed/23274926.

247. Jordan K, Kinitz I, Voigt W, et al. Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur J Cancer 2009;45:1184-1187. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19135359.